Beta Finch - S&P 100 - EN

More earnings analysis: https://betafinch.comGroups: AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)──────────WELCOME TO BETA FINCH, your AI-powered earnings breakdown of the companies moving markets. I'm Alex.JORDAN: And I'm Jordan. Today we're digging into Oracle's fiscal Q1 2027 report, and Alex, this one's got some big numbers in it.ALEX: It really does — but before we get into it, quick reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good, now let's get into it because Oracle's CFO Hilary Maxson used the word "acceleration" to describe the quarter, and honestly, the numbers back that up.ALEX: Total revenue hit a record $19.3 billion, up 30% year-over-year. What's notable is that revenue actually grew sequentially from Q4 to Q1 — historically that hasn't happened for Oracle. A strong Q4 usually meant a softer Q1.JORDAN: Right, and the real engine here is cloud infrastructure — OCI revenue was $7.4 billion, up 121% year-over-year. That's after 93% growth last quarter, so this business is actually speeding up, not slowing down.ALEX: Cloud apps grew a more modest 10%, but within that, Fusion grew 14% and industry apps grew over 20%. Non-GAAP EPS came in at $1.92, up 30%. And then there's the RPO number — remaining performance obligations jumped $26 billion in just one quarter.JORDAN: That RPO detail is worth pausing on. Management said the vast majority of that new backlog came through prepayments or "bring your own hardware" arrangements — meaning it doesn't require Oracle to put up more of its own capital. They now expect about half of total RPO to convert into revenue over the next 36 months.ALEX: Which matters a lot for the CapEx conversation, because Oracle spent $28 billion in CapEx this quarter alone, leading to negative free cash flow of $5 billion. Full-year CapEx guidance stays at $90-95 billion.JORDAN: On the Q&A, one exchange stood out to me — an analyst pushed CFO Hilary Maxson on when free cash flow turns positive again. She wouldn't give a timeline but said each data center project, once ramped, converts to free cash flow at close to 100% of post-tax EBITDA, essentially calling the business "self-funding" over time.ALEX: There was also a good back-and-forth on gross margins, which declined this quarter as expected. Maxson was pretty clear that operating margin — which held flat around 42% — is the metric she wants investors focused on, not gross margin, since the infrastructure business is structurally lower-margin but requires much less R&D and sales spend.JORDAN: On the infrastructure side, Co-CEO Clay Magouyrk shared some eye-popping delivery stats — 850 megawatts of AI capacity and over 300,000 GPUs delivered since Q4, almost triple what they delivered in all of Q4. GPU utilization sits at 97.9%, and — this one surprised me — GPUs coming up for renewal are actually being renewed or resold at a 20% premium to their original contracts.ALEX: That's a strong signal on hardware longevity in a market that's been nervous about AI infrastructure depreciation. Magouyrk also addressed concerns about delays at the New Mexico and Wisconsin data centers directly, saying neither will impact fiscal 2027 revenue guidance, and stressed Oracle has a broad, diversified pipeline of sites so no single delay creates a major hit.JORDAN: On the apps side, Co-CEO Mike Sicilia leaned into the AI-agents story — customers used embedded AI capabilities more than 150 million times in the quarter, AI agents executed 3.5 million times in production, nearly doubling quarter-over-quarter, and there are now over 2,300 AI agents live with customers, up 90% sequentially.ALEX: They also announced NetSuite Next, a new AI-infused version of NetSuite, and noted their AI Connector Service linkThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: CHIPS (https://betafinch.com/groups/CHIPS), AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)──────────WELCOME TO BETA FINCH, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Broadcom's fiscal Q3 2026 numbers—and folks, these are some genuinely wild numbers.ALEX: Before we get into it, quick reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And it's a good quarter to have that disclaimer front and center, because Hock Tan basically stood up and said "we're just getting started," and then backed it up with a $230 billion revenue forecast for 2028.ALEX: Let's start with the headline numbers. Q3 revenue came in at $29.6 billion, up 86% year-on-year. Operating income hit $20.1 billion, up 92%, with a record 68% operating margin. And free cash flow? $13.7 billion, 46% of revenue.JORDAN: Those margins are the story for me. Gross margin actually dipped slightly, down to about 75%, because AI chips carry more memory content and lower margins than the rest of the business. But operating margin still climbed because revenue is growing so much faster than expenses. That's operating leverage doing exactly what it's supposed to do.ALEX: Right, and the AI piece specifically—AI semiconductor revenue was $16.7 billion for the quarter, more than tripling year-over-year. That's now 56% of total revenue, up from 49% just last quarter.JORDAN: This company has essentially transformed into an AI infrastructure company that happens to also sell broadband chips and VMware software.ALEX: Speaking of which, let's talk customers, because this is where it gets interesting. Broadcom has six custom AI chip customers, but Hock Tan really zeroed in on four: Google, Anthropic, OpenAI, and Meta.JORDAN: The Google relationship is the elder statesman here—a decade of TPU development, and they just signed a long-term deal for "multi-tens of billions of dollars" of TPUs annually. They shipped the new Ironwood TPU v7 this quarter and are already ramping the next-gen v8i.ALEX: But the real headline is Anthropic. Tan said Anthropic is on track to become Broadcom's largest XPU customer in 2027, deploying 5 gigawatts of TPU v8i next year and then 10 more gigawatts in 2028.JORDAN: And OpenAI isn't far behind—their custom chip, nicknamed Jalapeño, is already reportedly outperforming Nvidia's Grace Blackwell in inference workloads at, according to Tan, less than half the cost. OpenAI's on pace for over 5 gigawatts by 2028, making them Broadcom's second-largest customer.ALEX: That "half the cost" line is the thesis of the whole call, honestly. Custom silicon, co-designed for a specific model's workload, beats a general-purpose GPU on performance and cost. That's Broadcom's pitch to the market.JORDAN: Now let's talk about the number that got everyone's attention: guidance. Q4 AI revenue guided to $21.7 billion, up 236% year-on-year. Full fiscal 2026 AI revenue now expected at $58 billion.ALEX: And then they went further than usual—giving multi-year guidance. AI revenue is expected to double to $115 billion in fiscal 2027, then double again to $230 billion in fiscal 2028.JORDAN: That's an unusually bold move for a company to lock in two years out. And CFO Amie Thuener was clear they don't plan to update it quarterly—so this is a stake in the ground, not a rolling estimate.ALEX: On the Q&A, analysts pushed hard on whether that's really achievable. Stacy Rasgon from Bernstein did some math on gigawatts versus dollars, and Tan clarified something important: not all the gigawatt capacity they've outlined will necessarily be "deployed" in that window—some of it depends on data centers, power, and shells being physically rThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────WELCOME TO BETA FINCH — PANW Q4 FY2026ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, here with Jordan, and today we're digging into Palo Alto Networks' fiscal Q4 2026 results. This one's a big report to close out their fiscal year.JORDAN: Before we jump in — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.ALEX: Right, so let's get into it, because Palo Alto had a genuinely record quarter. RPO — that's remaining performance obligations, basically the backlog of contracted future revenue — crossed $20 billion for the first time, landing at $21.2 billion, up 34%.JORDAN: And the number that really jumped out to me was Next-Generation Security ARR, or NGS ARR, hitting $9.1 billion, up 63%. They added almost $1 billion in net new NGS ARR in a single quarter. CFO Dipak Golechha pointed out that's roughly what the entire company's NGS ARR was back in his first quarter as CFO in 2021. That's the kind of comparison that really puts scale into perspective.ALEX: Total revenue for the quarter was $3.41 billion, up 34%, and full-year revenue came in at $11.5 billion, up 24%. Non-GAAP EPS beat guidance at $1.02, and operating margin for the year expanded to 29.2%.JORDAN: What's notable is that margin expansion happened while they were digesting their two biggest acquisitions ever — CyberArk, now rebranded Idira, and Chronosphere. Usually big M&A drags on margins for a while, but management said CyberArk's cost synergies are three to six months ahead of schedule.ALEX: Let's talk strategy, because CEO Nikesh Arora spent a lot of time on what he called three AI "inflection points" over the last several months — the shift from prompting to autonomous agents, the "Mythos moment" where AI models got scary good at finding vulnerabilities, and now a move toward open-weight, sovereign AI models. His overall thesis: all three point toward the same conclusion.JORDAN: Which is platformization — get customers to consolidate onto one unified security architecture instead of stitching together point products. They hit about 220 net new "platformizations" in the quarter, more than double the pace from two years ago, and platformized customers are showing net revenue retention above 120%.ALEX: They also called out some serious deal sizes — a $126 million deal with a global telecom, $72 million with an IT services firm, $53 million with a payments company. And Prisma AIRS, their AI security product, crossed $100 million in ARR in just four quarters — fastest product scale in company history.JORDAN: XSIAM, their security operations platform, is also cruising — over $700 million in ARR, up 70%, past 1,000 customers. And on the observability side, since closing Chronosphere, that ARR has more than doubled past $500 million. Combined, XSIAM and observability are now a billion-dollar-plus business that basically didn't exist a few years ago.ALEX: There was also a bit of breaking news on the call — they closed an acquisition of a company called Console the same day, focused on AI-driven IT and security operations, folding into their Cortex team.JORDAN: On the Q&A side, I thought the most candid moment was Nikesh basically saying M&A isn't a strategy for them — it's a consequence of watching 40 or 50 funded startups and jumping in when one of them nails a technology shift before Palo Alto's internal roadmap gets there. Refreshingly blunt for a CEO.ALEX: There was also a fun exchange about the CyberArk integration — a new "Modern PAM" product just went GA, and Nikesh made the case that identity security for AI agents and machine identities is a wide-open category with no established leader yet, which is where he thinks Idira has a real head start.JORDAN:This episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)──────────WELCOME TO BETA FINCH — MEDTRONIC Q1 FY2027ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Medtronic's fiscal 2027 first quarter — and it's a big one.JORDAN: Yeah, a lot to unpack here. Big beats, a couple of surprise M&A announcements, and a robotics story that's getting more interesting by the day.ALEX: Before we jump in, quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: With that out of the way, let's get into the numbers, because they were strong.ALEX: $9.8 billion in revenue, up 13.7% organically, adjusted EPS of $1.45 — both well ahead of what analysts were expecting. Now, a chunk of that growth came from an accounting quirk: fiscal 2027 is a 53-week year, and that extra week added about 670 basis points to growth this quarter.JORDAN: Right, but even stripping that out, CFO Thierry Piéton said it was their strongest quarterly performance in nearly eight years, excluding COVID comparisons. So this wasn't just a calendar trick — the underlying business is actually accelerating.ALEX: And it was broad-based. CEO Geoff Martha kept hammering that point — it's not one hot product carrying the quarter, it's basically every major business line pulling its weight.JORDAN: The headline story, though, is Cardiac Ablation Solutions — CAS. That business grew 88% worldwide, 139% in the U.S. They crossed $2 billion in trailing twelve-month revenue, ahead of schedule. Their Sphere-9 catheter picked up nine points of U.S. market share this quarter alone.ALEX: Nine points in one quarter is wild for medtech.JORDAN: It really is. And they're guiding CAS to grow at 2.5 times the broader electrophysiology market for the full year — even upgraded that to more than 3x for Q2. The U.S. installed base for their Affera system grew 35% sequentially, on top of 40% the quarter before.ALEX: Which tells you they're nowhere near saturated. Management said 75% of that installed base is still concentrated in high-volume hospital centers, so there's a long runway into smaller accounts.JORDAN: Beyond CAS, Cardiac Rhythm Management grew 15%, Cranial & Spinal Technologies grew 13%, and Surgical — their biggest unit at over $6 billion a year — grew 9%. Pelvic health jumped 15%, largely thanks to Altaviva, where procedures doubled sequentially.ALEX: Now let's talk strategy, because Medtronic made two acquisition-adjacent announcements the same morning as earnings. First, a $700 million strategic investment and distribution deal with Cornerstone Robotics for their Sentire surgical robot, outside the U.S.JORDAN: This one got some pointed questions on the call. One analyst basically asked, "Does this mean you've lost confidence in Hugo, your own robot?" And Martha pushed back hard — said it's the opposite. Hugo's on track to hit 50,000 procedures by year-end, growing at twice the market rate. Cornerstone is about extending reach into international markets where Hugo isn't the right fit, not replacing it.ALEX: Basically building a multi-platform robotics portfolio instead of betting everything on one system.JORDAN: Exactly — and Thierry noted the financial impact this year is minimal, mostly just some foregone interest on that investment, but they expect real revenue and margin lift starting in fiscal 2028.ALEX: The second deal was Pi-Cardia, in structural heart — first FDA-cleared technology for leaflet modification in TAVR procedures for patients at risk of coronary obstruction. That's part of a broader doubling-down in structural heart, alongside their earlier investment in Anteris.JORDAN: On guidance, they raThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex.JORDAN: And I'm Jordan. Today we're diving into Zoetis, ticker ZTS, the animal health giant. Q2 2026 results, and Alex, this one's a bit of a bumpy ride.ALEX: It really is. But before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good to have that out front. So let's set the scene. Zoetis reported second quarter revenue of $2.5 billion — flat on a reported basis, actually down 1% organically. Adjusted net income came in at $781 million, down 2% organically. And here's the headline: they cut full-year guidance.ALEX: Yeah, this wasn't a small tweak either. New revenue guidance is $9.12 to $9.32 billion, which works out to a decline of 3% to 1% for the year. Adjusted net income guidance dropped to a range implying a decline of 9% to 5%. That's a meaningful reset.JORDAN: So what happened? Basically, the U.S. Companion Animal business — think dogs and cats, not cattle and chickens — got hit hard. Revenue there was down 11% in the U.S. Fewer vet visits, pet owners being more price-conscious, and a lot more competitors piling into categories Zoetis basically invented, like dermatology treatments.ALEX: Right, and that's the key tension here. Their blockbuster drug Apoquel and the whole Key Dermatology franchise — U.S. dermatology revenue was down 18% in the quarter. New competitors are using aggressive discounting and rebates to steal share, and it's not growing the overall market, it's just splitting up a shrinking pie.JORDAN: Even so, Zoetis still holds about 86% in-clinic share in U.S. dermatology, even after losing 10 points year-over-year. So they're still dominant, just under real pressure for the first time in a while.ALEX: And parasiticides — flea, tick, heartworm meds like Simparica — were basically flat globally, with the U.S. side down 6%. Management said it's less about a specific competitor and more about a broader pullback in vet visits.JORDAN: But here's the plot twist — it's not all bad news. Livestock had a phenomenal quarter, up 11% globally, and 23% in the U.S., partly boosted by demand for cattle parasiticides tied to that New World screwworm outbreak. And Diagnostics grew 12%, driven by point-of-care testing demand.ALEX: So basically, the pet side is struggling, but the farm animal side and the diagnostics side are picking up a lot of the slack.JORDAN: Exactly — that diversification is doing real work for them right now.ALEX: Let's talk strategy, because CEO Kristin Peck was pretty clear about their playbook. Instead of cutting list prices — which she called a "permanent structural change" — they're doing what's called gross-to-net investment. Basically targeted rebates, promotions, and bundling deals to protect market share without blowing up their pricing structure long-term.JORDAN: It's a defend-the-fort strategy. Protect volume and share now, keep the sticker price intact, and hope the competitive intensity eases once the market sorts itself out. CFO Wetteny Joseph said full-year price realization could land anywhere from flat to down 2%, depending on how aggressive they need to get.ALEX: There's also a leadership shakeup worth mentioning. Wetteny Joseph, the CFO, is stepping down after five years — a new hire, Jay Saccaro, is coming in not just as CFO but in a newly created combined CFO and Chief Operating Officer role, overseeing manufacturing and supply chain too. That's a pretty significant restructuring of the C-suite, aimed at sThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL)──────────**BETA FINCH: Walmart Q2 FY2027 Earnings Breakdown**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.JORDAN: And I'm Jordan. Today we're digging into Walmart's fiscal second quarter 2027 results.ALEX: Before we jump in — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good ground rules. So, Alex, Walmart just posted a really strong quarter. Where do we start?ALEX: Let's start with the headline numbers. Enterprise sales grew 5% in constant currency — that's the top end of their guidance. Adjusted operating income was up over 17%, and EPS grew more than 19%. Walmart U.S. comps came in at 2.6%, Sam's Club U.S. hit 4.4%, and International was up nearly 8%, led by China and India.JORDAN: But here's the twist — a good chunk of that operating income growth wasn't "organic," so to speak. Walmart received about $2.9 billion in tariff refunds this quarter, and that added roughly 750 basis points to operating income growth. Strip that out, and underlying profit growth was still solid — at the top end of their 7-10% guidance — but the headline number is inflated by a one-time item.ALEX: Right, and CFO John David Rainey was upfront about this. He basically said, "look at Q2 and Q3 together" to get the real picture, because they're plowing a lot of that refund money right back into price cuts rather than just letting it flow to the bottom line.JORDAN: Which explains the rollback numbers — Walmart U.S. had over 11,000 rollbacks by the end of the quarter, up from 7,200 at the end of Q1. That's a huge jump, and CEO John Furner called it one of the highest counts he can remember.ALEX: It's a pretty deliberate strategy — take a windfall from tariff refunds, funnel it into lower prices on things like ground beef and pantry staples, and try to lock in market share. Furner mentioned food share gains were some of the strongest they've seen in a while.JORDAN: And that's the bet, right? Price investments now, in hopes it builds durable trust and share gains that outlast the promotional period. Management was pretty candid that there's a lag — you see unit growth first, and the real payoff comes over months, not days.ALEX: Let's talk about the stuff that weighed on results, too. Health and wellness was a real drag this quarter — that's their pharmacy business. New regulation called "Maximum Fair Price" for certain drugs hit comp sales by about 125 basis points, worse than they'd expected. They also lost the GLP-1 drug tailwind that helped in prior years.JORDAN: Which is interesting because if you back out health and wellness, their core categories — grocery, general merchandise — have been remarkably steady, in that 3-4% range for two and a half years. So the topline wobble is really a pharmacy story, not a "Walmart is losing its core mojo" story.ALEX: Now, the part I find genuinely exciting is the platform story — eCommerce, advertising, membership, Marketplace. Global eCommerce grew 23%. Advertising was up 38% globally. Marketplace in the U.S. grew 52%. And membership fee income hit an all-time high, up 17%.JORDAN: This is the piece investors should really pay attention to. Rainey made a striking comparison — Walmart's U.S. comp was only about 2.5%, but operating income grew 10% excluding tariff effects. That's four times the revenue growth rate, and he said they haven't seen that kind of profit leverage relative to comp sales in two decades.ALEX: Because these newer businesses — advertising, Marketplace, membership — carry much higher margins, and they're growing faster than the core retail business. Roughly half of profit growth this quarter came from those areas.JORDAN: TheThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Vertex Pharmaceuticals' second quarter 2026 results — and there's a lot going on: strong numbers, a major acquisition, and pipeline news across four disease areas. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Alright, Alex, let's start with the headline numbers because they're pretty solid.ALEX: Yeah, Vertex posted $3.3 billion in total revenue for Q2, up 12% year-over-year. That's driven largely by the cystic fibrosis franchise, which grew 11%, but also some real acceleration from the newer products.JORDAN: Right, and this is the part I find genuinely interesting — CASGEVY, their gene therapy for sickle cell disease and beta thalassemia, brought in $76 million this quarter. That's roughly 75% sequential growth and over 150% year-over-year. They had more infusions in the first half of 2026 than in all of 2025 combined.ALEX: That's a huge inflection point. And it's not slowing down either — they had over 100 patient initiations for a third straight quarter, plus a pediatric approval for ages two to eleven that came through in just 53 days post-filing.JORDAN: Then there's JOURNAVX, their non-opioid pain drug, at $50 million in revenue — about 70% sequential growth. The prescription numbers are climbing fast too, roughly 535,000 scripts this quarter. But here's the nuance: gross-to-net is still messy because of a patient support program covering people whose insurance has restrictions like quantity limits.ALEX: Management said that normalizes more toward branded-drug norms in the first half of 2027, so investors watching margins on JOURNAVX should expect some lumpiness for a few more quarters.JORDAN: On profitability — non-GAAP EPS came in at $4.73, up 5% year-over-year. Gross margin was 85.6%, a slight step down from Q1, which they attributed to product mix as CASGEVY, which costs more to manufacture, becomes a bigger slice of revenue.ALEX: And they raised full-year revenue guidance to $13.1 to $13.2 billion, reiterating that $500 million-plus target for non-CF revenue this year.JORDAN: Now let's talk about the big strategic move — the Crinetics Pharmaceuticals acquisition. This is roughly an $8.8 billion deal, expected to close in Q3.ALEX: This is Vertex adding a fifth commercial pillar — rare endocrine diseases like acromegaly, CAH, and Cushing's syndrome. The two lead assets from Crinetics, paltusotine and atumelnant, are pegged at a combined peak sales opportunity of about $5 billion.JORDAN: It's being funded through cash on hand plus a $4.5 billion term loan, and management said it should become accretive to operating income in 2029 — so this is a multi-year bet, not an immediate earnings boost.ALEX: Let's talk pipeline, because there's a lot moving. The renal franchise is arguably the most important near-term catalyst — povetacicept, or "Povi," for IgA nephropathy has an FDA decision date of November 30th after a really strong phase III interim analysis.JORDAN: And on the call, Reshma Kewalramani, the CEO, made a pretty confident case for Povi's differentiation — she cited a 52% reduction in proteinuria, which she called numerically the best in class, plus once-monthly dosing via a small-volume auto-injector patients can use at home.ALEX: There was also a great analyst question about how Vertex sees eGFR data compare against a competitor's recently published numbers. Reshma's answer was essentially: strong proteinuria reduction should translate to GFR stabilization, and Vertex believes Povi's numbers on proteinuria, hematuria, and other biomarkersThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────BETA FINCH — Uber Technologies (UBER) Q2 2026 Earnings BreakdownALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.JORDAN: And I'm Jordan. Today we're digging into Uber's second quarter 2026 results — and Alex, this was a loaded call. Delivery Hero, autonomous vehicles, a Waymo update — there's a lot here.ALEX: There really is. But before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good, let's get into the numbers.ALEX: So gross bookings came in at more than $58 billion, up 22% year-over-year — that's above the high end of guidance, and it's the fourth straight quarter above 20% growth. Non-GAAP EPS was up 35%, and trailing 12-month free cash flow crossed $10 billion for the first time ever.JORDAN: That free cash flow number is the headline for me. Ten billion trailing twelve months — that's real operating leverage, not just top-line growth. And it's giving them room to do something pretty aggressive: the agreement to acquire Delivery Hero.ALEX: Right, and that deal basically doubles the number of markets where Uber can run both mobility and delivery side by side — pushing them toward nearly 100 markets. CFO Balaji Krishnamurthy laid out the integration timeline: assuming a close in the second half of 2027, they'd spend 2028 planning, then execute the core platform migration in 2029.JORDAN: That's a long runway. And notably, they actually pivoted about $4 billion of capital toward that deal in Q2 — buying Delivery Hero stock on the open market to be ready to move fast. That's part of why buybacks slowed to $3.5 billion so far this year instead of hitting their usual 50%-of-free-cash-flow pace. Balaji said they're "steadily" rebuilding repurchases — and when pushed on timing, he said months, not quarters.ALEX: Let's talk autonomous vehicles, because Dara Khosrowshahi spent a lot of time here. Uber's live in seven cities with AV partners right now, on track for 15 by year-end — Zoox in Vegas, Wayve in London and Tokyo, a Nuro-Lucid launch in the Bay Area, Baidu, Pony, more.JORDAN: What stood out to me is how he framed the whole AV landscape — comparing it to the foundation model race. Instead of one company winning everything, you get multiple players — Waymo, Zoox, Wayve, Nuro, Rivian, NVIDIA — and Uber's positioning itself as the commercialization layer underneath all of them, not betting on a single winner.ALEX: Which matters given the Waymo headlines lately. Dara addressed it directly — said Waymo remains an important partner, they'll keep operating in Austin and Atlanta into next year, but Uber's deliberately diversifying so they're not dependent on one AV provider.JORDAN: And the scale context he gave was useful — AVs are doing hundreds of thousands of trips per week against Uber's total of 300 million weekly trips. That's under half a percent of volume. So this is very much still an early-innings story, even with all the partnership headlines.ALEX: There was also a really interesting tidbit on the economics — Dara said Uber's built-in demand drives utilization of mid-to-high-20s, even low-30s trips per vehicle per day for AV partners. That's a meaningful data point on how Uber's platform accelerates the monetization case for these robotaxi partners.JORDAN: On the U.S. mobility side, Balaji broke down what's driving the acceleration everyone's been watching for — insurance cost savings being reinvested into markets like California, product innovation on both ends of the spectrum — Uber Reserve and Black on the premium side, Wait & Save on the value side — and then sparse markets, where less than 10% of eligible U.S. consumers have used Uber in the past year, versus overThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL)──────────**BETA FINCH — TJX Companies (TJX) Q2 Fiscal 2027 Earnings Breakdown**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.JORDAN: And I'm Jordan. Today we're digging into TJX Companies — the parent of TJ Maxx, Marshalls, HomeGoods, and Sierra — and their second quarter fiscal 2027 results.ALEX: Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good to have that out of the way. So, Alex, headline number first — how'd they do?ALEX: Pretty strong quarter overall. Consolidated comp sales up 4%, which beat their own plan. Adjusted diluted EPS came in at $1.22, up 11% year-over-year, and also well above what they'd guided to. Off the back of that, they actually raised full-year guidance — now looking at $5.15 to $5.20 in adjusted EPS for the year, up 9-10% from last year.JORDAN: That's a solid beat-and-raise. But there was one wrinkle in there — Marmaxx, which is their biggest division by far, TJ Maxx and Marshalls combined, only grew comps 1%. Everybody else was humming.ALEX: Right, and that's really the story of this call. HomeGoods put up a 7% comp, TJX Canada was up 6%, and TJX International — that's Europe and Australia — was up 7% as well. Those three carried the quarter while Marmaxx lagged.JORDAN: CEO Ernie Herrman was pretty candid about what happened there. He called it "self-inflicted" — basically said they didn't have the right merchandise mix in the right stores at the right time. Not a demand problem, not a competitive pricing problem.ALEX: Yeah, and he made a point of saying they actually checked — their comps near direct off-price competitors were basically identical to comps in stores without nearby competition. So this wasn't about getting out-priced by anyone. It was execution — certain categories where they just didn't have enough of the right inventory, so shoppers walked in and couldn't find what might've been an impulse buy.JORDAN: What I found interesting is he framed the fix as already underway — said sales were improving into August, and he expects to be back to that normal 2-3% comp range for Marmaxx by the fourth quarter, in time for holiday.ALEX: They also said they've built in some new systematic planning processes to catch this kind of mix issue earlier. And notably, everyone from buyers up to Herrman himself was looped into fixing it — so it sounds like this got serious internal attention.JORDAN: Meanwhile, HomeGoods was the real standout. Let's talk about that — 7% comp, and adjusted segment profit margin jumped 240 basis points to 12.4%. That's a big move.ALEX: Herrman was genuinely excited about that one. He talked about HomeGoods becoming this dual-purpose destination — not just the treasure-hunt impulse shopping people associate with it, but now also a place people go for everyday consumable staples, like replenishing kitchen or home goods regularly. That combination is driving really consistent traffic.JORDAN: And on the margin side, CFO John Kirby noted it's a mix of the sales leverage from that strong comp, some operational efficiencies, and lower tariff costs boosting merchandise margin.ALEX: Speaking of tariffs — that's a thread running through this whole call. TJX actually received tariff refunds during the quarter, and all the numbers we're discussing are on an adjusted basis that strips those out, along with some related compensation accruals tied to them.JORDAN: Worth flagging for listeners — gross margin was up 70 basis points to 31.4% in the quarter, largely tariff-driven favorability. But looking into the back half, management guided gross margin roughly flat to slightly downThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)──────────WELCOME TO BETA FINCH, YOUR AI-POWERED EARNINGS BREAKDOWN.ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Palantir's Q2 2026 print — and folks, this one's a doozy. But before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And we need that disclaimer today more than usual, because Alex Karp did not hold back on this call. But let's start with the numbers, because they're genuinely wild. Revenue grew 93% year-over-year — that's Palantir's highest growth rate ever, at this scale.ALEX: Right, and it's not a small-company effect either. We're talking $1.935 billion in quarterly revenue. The U.S. business specifically grew 115% year-over-year and is now over 81% of total revenue. U.S. commercial — meaning private companies, not government — accelerated to 149% year-over-year growth. That's up from an already huge number last quarter.JORDAN: The bookings numbers back that up too. They closed $2.132 billion in U.S. commercial TCV — total contract value — in a single quarter. That's nearly $800 million above their previous best quarter ever. And 220 deals worth a million dollars or more, 73 of those over $10 million. Net dollar retention hit 157%, up 700 basis points sequentially — meaning existing customers aren't just staying, they're massively expanding their spend.ALEX: On profitability, this wasn't a "growth at all costs" story either. Adjusted free cash flow was $1.22 billion, a 63% margin. GAAP net income crossed a billion dollars for the first time. Rule of 40 score — that combines growth plus margin — hit 155. For context, 40 is considered good for software companies. They're at nearly four times that.JORDAN: And they raised guidance meaningfully. Full-year revenue guidance moved up to around $8.15 billion, which they called their largest-ever guidance raise. U.S. commercial guidance now sits above $3.4 billion for the year, implying at least 134% growth.ALEX: So let's talk strategy, because CTO Shyam Sankar and CEO Alex Karp spent a lot of time on this idea of "AI sovereignty." The pitch is basically: if you're an enterprise just buying tokens from a frontier AI lab, you're paying to leak your own proprietary data and expertise into that lab's training pipeline — helping them build tools that could eventually compete with you. Palantir's argument is that their platform, AIP, lets companies keep control of their data, their models, and the "weights" — meaning the actual trained intelligence — inside their own security boundary.JORDAN: There was a great anecdote about this — Shyam described a bake-off at a major tech company between a frontier AI lab's team and Palantir's forward-deployed engineers. Same customer, same timeline, same underlying models. The lab reportedly failed to deliver on a ticketing automation problem, while Palantir's team built something that converted into a $10 million contract. Whether or not you love the framing, it's a concrete data point on why enterprises are choosing them.ALEX: They also introduced this term "benchmaking" versus "benchmaxing" — basically arguing that generic AI benchmarks don't matter much; what matters is building a benchmark specific to your business and optimizing toward that. They gave an example where an open-weight model, Nemotron Ultra, with no extra tuning, beat frontier models on five actual production tasks within 24 hours of testing.JORDAN: On the government side — which is still nearly half of total revenue — U.S. government revenue grew 90% year-over-year. Their Maven platform now has over 25,000 buildersThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Pfizer's second quarter 2026 results, and there's a lot to unpack — from a CFO transition to some really important pipeline news. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And there's plenty to research here, Alex. Let's start with the headline news that isn't even about the numbers — Pfizer's CFO Dave Denton is departing, and Cecile Guegan is stepping in as interim CFO. She's not new to the building though — she's been deeply involved in the Seagen, Metsera, and Biohaven deals and Pfizer's capital allocation strategy.ALEX: Right, so this feels like a continuity move rather than a shake-up. Now let's get to the numbers. Q2 revenue came in at $15 billion, up just 1% operationally year-over-year — but here's the key detail: strip out COVID products, and the underlying business actually grew 5% operationally.JORDAN: That's the story of this whole quarter — COVID is a drag, everything else is humming. Adjusted diluted EPS was $0.77, beating expectations. And get this — Pfizer has now beaten EPS expectations for ten straight quarters, and revenue expectations in nine of the last ten. That's a pretty remarkable execution streak.ALEX: They also raised full-year revenue guidance to a range of $60.5 to $62.5 billion, up $500 million at the midpoint, even while cutting their COVID revenue forecast from $5 billion to $4 billion.JORDAN: Which tells you how strong the non-COVID business is performing to more than offset that. EPS guidance was reaffirmed at $2.80 to $3, though that now absorbs a $0.10 hit from the Innovent Biologics deal that closed in Q3.ALEX: Let's talk about those big acquisitions, because this is really the crux of Pfizer's growth story. The Seagen, Metsera, and Biohaven deals — revenue from acquired products grew 25% operationally. PADCEV, the bladder cancer drug from Seagen, just got FDA approval expanded to muscle-invasive bladder cancer regardless of cisplatin eligibility, and it grew over 20% this quarter.JORDAN: And on the Metsera side, that's the obesity bet — nirubenatide, their monthly GLP-1 candidate. They're targeting a $150 billion obesity market and aiming for first approval in 2028. They shared data suggesting it could be competitive with — maybe even better than — some existing weekly therapies like Wegovy, though as always, cross-trial comparisons come with caveats.ALEX: Biohaven's NURTEC is also doing well, still leading the oral CGRP migraine class, with new trials underway for chronic and menstrual migraine.JORDAN: Now, it wasn't all good news. There was a real setback in oncology — the phase III trial for sigvotatug vedotin, or SV, missed its primary overall survival endpoint in second-line-plus non-small cell lung cancer. That contributed to a $4.3 billion non-cash impairment charge, which is why Pfizer actually posted a GAAP loss per share of $0.04 this quarter.ALEX: But management pushed back on writing off SV entirely — they highlighted a subgroup of patients on just one prior therapy that showed a 2.5-month survival benefit, and they're leaning into earlier-line lung cancer combos with pembrolizumab, where phase I data showed an 82% response rate.JORDAN: There's also encouraging news on mevrometostat, their prostate cancer drug being developed alongside XTANDI. Phase I data showed it roughly doubled progression-free survival, and the market really zeroed in on this during Q&A — analysts are watching the MEV-Pro1 readout expected in Q4.ALEX: Speaking of Q&A, one exchange I found telling was about the dividend. An analystThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: MAG7 (https://betafinch.com/groups/MAG7), CHIPS (https://betafinch.com/groups/CHIPS), AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)──────────**Beta Finch: NVIDIA Q2 FY2027 Earnings Breakdown**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.JORDAN: And I'm Jordan. Today we're diving into NVIDIA's fiscal Q2 2027 print — and there's a lot to unpack.ALEX: Before we get into it — quick note. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Alright, with that out of the way — Alex, NVIDIA just put up $96 billion in quarterly revenue. That's more than double year-over-year.ALEX: And it's the fourth straight quarter of accelerating growth, which is honestly wild for a company already this large. Data center revenue alone hit $89 billion, up 18% sequentially. Split that into two buckets: hyperscale revenue was $49 billion, up 13%, and then this other segment they call ACIE — that's NeoClouds, enterprise, sovereign AI — came in at $40 billion, up 25% sequentially and 138% year-over-year.JORDAN: That ACIE number jumps out to me. It's growing faster than the hyperscale business, and CFO Colette Kress made a point of saying it now represents roughly half of NVIDIA's data center business. That's not a side hustle anymore — sovereign AI alone tripled year-over-year.ALEX: Right, and they're guiding Q3 revenue to $108 billion, plus or minus 2%. For the full fiscal year 2028, they're now projecting about 70% revenue growth — but here's the catch, Jordan.JORDAN: The catch is that's a supply-constrained number, not a demand number. Jensen Huang was pretty blunt on the call — actual demand is closer to 100% growth. They simply can't build enough. Every cloud they serve is fully utilized.ALEX: Which is a good problem to have, but it does mean gross margins are getting squeezed. Memory pricing — DRAM specifically — has spiked way beyond what they expected. Gross margin is guided down to 74% in Q3, and they said it'll bottom out around 71-72% in Q4 before recovering to 72-73% next fiscal year once price increases kick in.JORDAN: That's the number I think investors are going to fixate on. Component costs eating into margins is a real headwind, even with revenue this strong.ALEX: Let's talk strategy, because there's a lot of new stuff here. First, the AWS expansion — Amazon's deploying an additional 2 million GPUs through fiscal 2029, plus their new Vera CPUs, some paired with the upcoming Rubin GPU.JORDAN: And Vera Rubin itself is the big story architecturally. They started production shipments this month, and Jensen's calling it the fastest product ramp in company history — already has purchase orders from every major hyperscaler, cloud, and OEM. The pitch is 30x higher throughput per megawatt and 35x lower token cost versus the previous Blackwell Ultra generation.ALEX: There's also this revenue-per-gigawatt trend they keep highlighting. Hopper was about $18 billion of NVIDIA revenue opportunity per gigawatt of data center capacity. Blackwell pushed that to $25 billion. Vera Rubin is $40 billion.JORDAN: That's the flywheel — each generation captures a bigger slice of the data center build-out, not just GPUs but CPUs, networking, even their new Groq LPU line for high-speed inference. It's less "sell a chip" and more "sell the whole factory."ALEX: Speaking of financing — this is where it gets a little more complicated. NVIDIA disclosed nearly $50 billion invested directly into frontier AI labs, plus new financing partnerships with six major capital providers — Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs, KKR — aiming to raise over $500 billion in third-party capital for AI infrastructure.JORDAN: And they addressThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────Welcome to Beta Finch, your AI-powered earnings breakdown for the news that's moving your portfolio.ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, here with Jordan as always, and today we're digging into Merck's second quarter 2026 numbers. Before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good disclaimer to lead with, because there's a lot to unpack here — this was a noisy quarter on paper but honestly a pretty exciting one underneath the hood.ALEX: Right, let's start with the headline numbers. Merck posted revenue of $16.6 billion, up 5%, or 4% if you strip out currency effects. Oncology and animal health carried a lot of that weight, plus growing contributions from newer launches.JORDAN: But here's where it gets interesting — on the bottom line, Merck actually reported a loss of $0.13 per share. That sounds alarming until you realize it's almost entirely a one-time accounting quirk.ALEX: Exactly. They completed the acquisition of Terns Pharmaceuticals this quarter, picking up a promising CML — chronic myeloid leukemia — drug candidate. That came with a $5.7 billion charge, and because it wasn't tax-deductible, their tax rate for the quarter ballooned to over 160%.JORDAN: Which tanked EPS by $2.31 a share. Take that out, and the underlying business is actually performing quite well. It's a classic case of "read past the GAAP headline number."ALEX: They also raised and narrowed full-year guidance — now expecting revenue between $66.3 and $67.3 billion, 2-4% growth, and full-year EPS of $2.66 to $2.76.JORDAN: Let's talk product performance, because this is really a story of "old reliable" versus "new and exciting." KEYTRUDA, the flagship cancer immunotherapy, grew 4% to $8.4 billion — still the workhorse, but management flagged that U.S. growth is moderating as it approaches peak penetration in a lot of indications.ALEX: Meanwhile the newer stuff is popping. WINREVAIR, their pulmonary hypertension drug, was up 75% to $588 million. WELIREG jumped 67%. CAPVAXIVE, their pneumococcal vaccine, up 40%.JORDAN: Those growth rates matter a lot for the bigger narrative here, which is what happens when KEYTRUDA eventually loses patent exclusivity around the end of the decade. CEO Rob Davis addressed this directly in the Q&A — he called it "more of a hill than a cliff," with a shallow dip and a fast return to growth, backed by more than $70 billion in commercial opportunity from over 20 new products.ALEX: And a big one this quarter was LIPFENDRA — the first oral PCSK9 inhibitor approved by the FDA, for lowering LDL cholesterol. It got fast-tracked through a national priority voucher process.JORDAN: This is a big deal because current injectable PCSK9 drugs only reach about 5% of the eligible market — mostly because doctors and patients don't love needles for a chronic condition. An oral pill could meaningfully expand that market. Davis was clear they're not trying to steal share from injectables, they're trying to grow the whole pie — 30 million Americans are on lipid therapy but not hitting their LDL targets.ALEX: There's also real pipeline momentum beyond LIPFENDRA. Sac-TMT, their Trop-2 antibody-drug conjugate for cancer, put up positive Phase III results in endometrial cancer — ahead of schedule. Same with tulisokibart, their ulcerative colitis drug, which hit positive Phase III results faster than expected too.JORDAN: Dr. Dean Li, their research chief, made a point of saying their confidence is actually higher now than it was back in January, because so many of these pipeline bets are reading out early and positive. That's not something yoThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into McDonald's second quarter 2026 results, and there's a lot to unpack — some real strategic news alongside a leadership change. Before we get into it, quick note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Yeah, and this one's juicy, Alex — because it's not the usual "everything's great" call. McDonald's actually came out and said, in Chris Kempczinski's words, "we don't have a strategy problem, we simply didn't execute."ALEX: Right, so let's start with the numbers. Systemwide sales grew 4% in constant currency, global comparable sales up 1.3%. Adjusted EPS came in at $3.38, up 5% on a constant currency basis. Solid, but not spectacular.JORDAN: And the real story is the U.S. — comp sales grew just 0.8% in the quarter, which was below expectations. International actually carried the day here, with IOM up 1.5% and the international developmental licensed markets up 1.9%, led by Japan posting its tenth straight quarter of positive guest counts.ALEX: So what actually went wrong in the U.S.? CFO Ian Borden broke it into pieces. They launched this new "everyday affordable price" menu — 10 items under $3 — in late April, but execution was spotty. Only about 60 to 65% of restaurants actually followed the recommended pricing.JORDAN: And here's the kicker — to fund that value push, they pulled back on digital offers and killed the Buy One, Add One for a dollar promotion, which apparently really annoyed their most loyal, high-frequency customers. Kempczinski flat-out called it "a bad trade."ALEX: Management said that alone accounted for about two-thirds of the traffic miss. The rest came down to their FIFA-themed marketing campaign in June underperforming expectations.JORDAN: There was also this operational overload problem — Chris painted a great picture of it, basically saying "put yourself in a restaurant manager's shoes." You've got K-Pop Demon Hunters merchandise going up, then three weeks later you're flipping the value menu, then a brand-new beverage platform launches, then FIFA. Crew members are getting whiplash, service times went up, satisfaction scores went down.ALEX: It's a good reminder that even a company with McDonald's scale and marketing muscle can trip over its own to-do list. Too much "new" at once, poorly sequenced.JORDAN: Right, and it bled into July too — Borden mentioned U.S. comps were actually slightly negative to start Q3. So this isn't fully behind them yet.ALEX: Now here's where it gets interesting — there's a leadership shakeup. Skye Anderson, previously COO of McDonald's USA, is stepping in as the new President of McDonald's U.S., effective immediately. Joe Erlinger, who ran the U.S. business for nearly seven years, is leaving the company.JORDAN: Chris was pretty deliberate about framing this as a planned transition, not a panic move — he name-checked Anderson's 26-year track record, including a stint leading the U.S. West zone where she drove over 30% comp sales growth. But the timing, right after a rough quarter, is obviously going to raise eyebrows.ALEX: On the brighter side — beverages. McDonald's launched a new beverage platform in the U.S., Canada, and Germany in May, and early results are beating expectations. Higher checks, strong food attachment, and more than half the traffic is coming after the lunch rush — which is exactly the low-volume window they want to fill.JORDAN: They're also leaning into Red Bull Energizers rolling out in the U.S. soon, and Australia just launched the platform in mid-July. This seems like a lThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Mastercard's second quarter 2026 results, and there's a lot to unpack — big numbers, a leadership shakeup, and some fascinating moves into AI-driven commerce.JORDAN: Yeah, this one's got a bit of everything. But before we get into it —ALEX: Right, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good, now let's get into it. Mastercard posted net revenue up 12% year-over-year, adjusted net income up 16%, and EPS of $5.04. That's a strong quarter, and honestly it came in above what management was expecting.ALEX: It really did. And one number that jumped out to me — value-added services, that's all the fraud, security, and consulting stuff Mastercard layers on top of its payments network — grew 18%. That's outpacing the core payments business by a good margin.JORDAN: Which tells you where the growth engine really is right now. Gross dollar volume worldwide was up 8%, cross-border volume up 12%, and switched transactions — that's transactions actually processed on Mastercard's network — grew 9%. All pretty healthy.ALEX: Let's talk about the elephant in the room first, though: the leadership transition. This was CFO Sachin Mehra's last earnings call in that role — he's moving to a new position as Chief Business Officer. Ling Hai, who's been running the Asia Pacific, Europe, Middle East and Africa region, steps in as CFO starting August 3rd.JORDAN: It was a pretty warm moment on the call, honestly. CEO Michael Miebach thanked Mehra for seven-plus years in the seat, and Mehra himself got a little sentimental, thanking analysts and investors for the relationship. Ling Hai even said he's looking forward to "leading the next earnings call."ALEX: Smooth transition, no red flags — just feels like normal succession planning at a company that's performing well.JORDAN: Agreed. Now, strategically, there were a few things I found really interesting. First, this switching technology partnership in the UAE. Mastercard is now building out the actual domestic payments switching infrastructure for the Central Bank of the UAE, working alongside their local scheme called Jaywan.ALEX: Which is a bit of a shift, right? Normally we think of Mastercard as just the network sitting on top of transactions. Here they're actually building and operating switching infrastructure locally.JORDAN: Exactly — Miebach called it "run anything anywhere," a strategy they've been building since 2022. They've done something similar in South Africa, and they're clearly eyeing this modular approach as a way to get access to transaction volume they wouldn't otherwise touch — even domestic transactions that don't run through Mastercard's global switch.ALEX: There's also a Latin America push — expanding their Alipay+ partnership into Mexico with Clip, a fintech with a huge merchant network. Remember, Mexico is a market where over 70% of consumer payments are still cash-based, so there's a massive digitization opportunity there.JORDAN: And speaking of frontier stuff — Mastercard rolled out something called Agent Pay for Machines. This is genuinely new territory: it's designed to let AI agents autonomously pay for things like API calls, cloud compute, or data access, at machine speed, with over 30 partners already signed on including Coinbase, Cloudflare, and Checkout.com.ALEX: This is the "agentic commerce" trend everyone's talking about. Miebach made an interesting distinction on the call — consumer and B2B agent-driven purchases can basically run through existing card rails just fine, but this true machine-to-machine, micro-transaction world is a genuinely new category, and MastThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL)──────────I'll write the podcast script now based on the transcript.WELCOME TO BETA FINCH, YOUR AI-POWERED EARNINGS BREAKDOWNALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Lowe's second quarter fiscal 2026 results, reported August 19th. Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good disclaimer to lead with, because this quarter has a little bit of everything — solid execution undercut by some messy competitive dynamics. Should be a fun one to unpack.ALEX: Let's start with the topline. Lowe's did $26 billion in sales for the quarter, up 8.3% year-over-year, but that growth is mostly acquisition-driven — comparable sales, meaning existing stores, only rose 0.2%. GAAP diluted EPS came in at $4.27, and adjusted EPS was $4.40, which included an $0.11 benefit from tariff refunds.JORDAN: And that $0.11 detail matters more than it sounds like at first. CFO Brandon Sink was clear that even excluding the tariff refund, adjusted EPS beat expectations. So the underlying business performed better than the headline number suggests — that refund wasn't propping up an otherwise weak quarter.ALEX: Right, and comp sales broke down interestingly by month — May was down 0.4%, June up 1.7%, July down 1.2%. Some of that swing is just calendar noise, the July 4th holiday shifted between June and July and moved about 75 basis points back and forth.JORDAN: But the more important July story wasn't calendar — it was competitive. Management said competitors used their own tariff refund dollars to slash prices, particularly in seasonal categories like grills, patio furniture, and live goods. Lowe's chose not to chase those promotions.ALEX: Yeah, CEO Marvin Ellison was pretty blunt about that in the Q&A — he said matching those prices "was not in our financial plan" and wasn't "financially prudent." Basically: we can see who got tariff refunds by looking at whose gross margin cratered.JORDAN: Which is a pretty sharp comment aimed squarely at competitors. But it also tells you something about Lowe's discipline here — they'd rather protect margin than chase a short-term share number in a category they view as transitory. Whether that's the right call long-term is the real debate for investors.ALEX: Let's talk about where the strength actually showed up, because it wasn't uniform. Lowe's has been leaning hard into what they call the "Total Home" strategy — basically diversifying beyond the DIY homeowner into professional contractors, online, and installed services.JORDAN: And that strategy is clearly doing the heavy lifting. Online sales grew nearly 16% — that's back-to-back quarters above 15%. Pro customers kept growing too, especially small and medium-sized contractors. Home Services, the "do it for me" installation business, also grew. Meanwhile, discretionary DIY spending — think big remodeling projects — stayed under pressure.ALEX: One thing that jumped out to me was Mylow, their AI shopping assistant. They said it's fielded over 25 million questions from customers and store associates combined, and customers who use it convert at three times the rate of those who don't.JORDAN: That's a genuinely strong stat. It's early days for how much AI tools move the needle in retail, but a 3x conversion lift is not a rounding error — that's a real behavioral signal. Worth watching whether that holds up as adoption scales further.ALEX: On the Pro side, they've been building out FBM and ADG — Foundation Building Materials and Artisan Design Group, two acquisitions aimed at bigger professional and construction customersThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Eli Lilly's Q2 2026 results, and Jordan, I'll just say it up front — this was a big one.JORDAN: Big is an understatement. But before we get into the numbers, our standard reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.ALEX: Right, with that said — let's talk numbers. Lilly's revenue grew 48% year-over-year in Q2. Their key products alone added almost $6.8 billion, and get this — oncology, immunology, and neuroscience combined grew 121% versus last year.JORDAN: That's a company firing on basically every cylinder. And the incretin franchise — Zepbound and Mounjaro — is still the engine room. Combined, those two brought in $14.9 billion in the quarter, contributing $6.3 billion of the total growth.ALEX: Gross margin ticked up to 86.3%, non-GAAP EPS came in at $8.38 — though that includes a $3.03 hit from acquired R&D charges, so the underlying number is even stronger. And naturally, they raised full-year guidance: revenue now expected between $85 and $87 billion.JORDAN: Which, by the way, is up $3 billion at the low end and $2 billion at the high end from prior guidance. That's not a small tweak — that's a company that's genuinely outperforming its own expectations.ALEX: Let's talk geography for a second, because the international story here is wild. China revenue grew 93% in constant currency. Rest of world — think Latin America, Asia — grew 136%. Lilly's international incretin market share is now around 55% globally.JORDAN: And this is the piece I think investors sometimes underweight — Mounjaro's global rollout is still in relatively early innings in a lot of these markets. Management basically said future growth outside the U.S. is going to come from market penetration, not just new country launches, since most of the big launch wave already happened last year.ALEX: Which actually ties into one of the more interesting analyst questions on the call — someone pushed back on guidance, basically asking "wait, doesn't this guide imply deceleration versus Q2?" And CFO Lucas Montarce had a pretty candid answer.JORDAN: Yeah, he pointed to a few real factors — there were some one-time favorable adjustments to rebate and discount estimates this quarter that won't repeat, last year's back half had a huge bolus of new-market Mounjaro launches that's now lapped, and there's normal seasonality — European summer holidays hit Q3, and diabetes has its own seasonal pattern in Q4. So it's less "conservative sandbagging" and more "the comp gets harder."ALEX: Fair enough. Now let's talk about the newer story here — Foundayo, their oral GLP-1. The U.S. launch has been a bit of a slow burn, but management said they're now seeing real inflection. Prescriber count went from 8,000 last quarter to 36,000 now, and the last week of July nearly doubled monthly volume.JORDAN: The Medicare GLP-1 Bridge Program is a big deal too — it launched July 1st and gives 20 million eligible Americans coverage for obesity GLP-1s at just $50 a month out-of-pocket. That's a 35% expansion in coverage overnight. Early signs are heavily skewed toward injectables — about 80% — but they're seeing real new-patient uptake on both fronts.ALEX: And internationally, the UAE numbers turned heads — $31 million in Foundayo sales in a single quarter, which is nearly half of total U.S. sales. One analyst flagged that as a signal of "explosive potential" once Foundayo rolls out more broadly, which management confirmed is coming mostly in 2027.JORDAN: On the pipeline side, retatrutide is the one to watch. Three positive Phase III trials — TRIUMPH-1, 2,This episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL)──────────**BETA FINCH — HOME DEPOT (HD) Q2 FISCAL 2026 EARNINGS BREAKDOWN**---ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan. Today we're digging into Home Depot's second quarter fiscal 2026 results, reported August 18th.JORDAN: Good one to cover — there's a lot going on here beyond the headline numbers.ALEX: There is. But before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good to have that out of the way. So, Alex, where do we start?ALEX: Let's start with the top line. Home Depot posted $47.9 billion in sales for the quarter, up 5.7% year-over-year. Comp sales — that's sales at stores open at least a year — grew 1.7% company-wide, with U.S. comps up 1.3%. Adjusted diluted EPS came in at $4.92, versus $4.68 a year ago.JORDAN: And importantly, management said results actually exceeded their own internal expectations. That's notable in this environment — housing turnover is sitting at historic lows, and big discretionary remodels are still under pressure. So beating expectations here is really a story about smaller projects.ALEX: Right, this was very much a "repair and maintenance" quarter. Think storage, electrical, hardware, plumbing — 13 of their 16 merchandising departments posted positive comps. Big, expensive kitchen and bath remodels? Still soft. But the bread-and-butter stuff is holding up well.JORDAN: What stood out to me is the ticket versus transaction split. Average ticket was up 2.8%, but transactions were actually down 1%. So people are spending more per visit, but fewer people are walking through the door. Big-ticket purchases over $1,000 were up 2.4%, which tells you there's still some appetite for larger single-item purchases — think appliances, portable power tools — even if it's not full-blown renovation spending.ALEX: Speaking of portable power, Billy Bastek, their merchandising EVP, called Q2 a record-setting quarter for portable power tools. That's been a real bright spot along with patio and, interestingly, appliances — where they've built out next-day delivery to nearly 60% of the population.JORDAN: Let's talk about the tariff piece, because this got a lot of analyst attention on the call. Home Depot received $730 million in IEEPA tariff refunds during the quarter, and $685 million of that flowed through to reduce cost of goods sold. That gave gross margin a roughly 145 basis point lift.ALEX: But — and this is the important nuance — that benefit was mostly offset by rising costs elsewhere. About 60 basis points of pressure from fuel, energy, and other input costs, plus another 60 basis points of margin dilution just from the mix effect of the GMS acquisition. Net-net, gross margin only rose about 25 basis points to 33.7%.JORDAN: CFO Richard McPhail was pretty direct about this — he said even without the tariff refund, they'd have beaten expectations anyway, it just would've shown up differently. He's basically pre-empting the narrative that Home Depot "missed" underlying profitability and needed the refund to bail them out.ALEX: Which makes sense given how the stock commentary was framing it going into the call. Now, strategically, the two big themes this quarter were the Pro customer and interconnected retail — meaning online, delivery, in-store tech all working together.JORDAN: The Pro business had a positive comp and actually outperformed DIY, which is a real accomplishment given how much of the housing market is frozen right now. A lot of that comes down to SRS Distribution and the GMS acquisition — those are the specialty distributors Home Depot has folded in to better sThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL)──────────**WELCOME TO BETA FINCH: HOME DEPOT Q2 2026**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Home Depot's second quarter fiscal 2026 numbers. Big one — the world's largest home improvement retailer, a lot of moving pieces this quarter.JORDAN: Lots to get into, including some tariff refund math that tripped up a few analysts on the call.ALEX: We'll get there. But first, the standard disclosure: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good to have that on record. So, headline numbers — Home Depot posted $47.9 billion in sales, up 5.7% year-over-year. Comp sales up 1.7% overall, 1.3% in the U.S. specifically.ALEX: And adjusted diluted EPS came in at $4.92, versus $4.68 a year ago. That actually beat expectations — management said the quarter exceeded what they'd planned for.JORDAN: Worth noting right up top — before the numbers, CFO Richard McPhail addressed CEO Ted Decker's temporary medical leave of absence. Leadership wished him a quick recovery and said Ann-Marie Campbell and the broader team are steering the ship in the meantime.ALEX: Good context to have. Now let's talk about what actually drove the quarter, because it's a broader story than just "big box retailer sells more stuff." Thirteen of sixteen merchandising departments posted positive comps — storage, electrical, hardware, power tools, plumbing, paint, flooring, you name it.JORDAN: And it wasn't just seasonal stuff either. Merchandising EVP Billy Bastek made a point of saying only 3 of their top 20 performing categories were seasonal — the "middle of the store," as he called it, core home improvement categories, is where the real strength showed up.ALEX: Portable power was a standout — Q2 was literally a record-setting quarter for portable power tools. And Pro customers outperformed DIY again, continuing a trend we've heard from Home Depot for a while now.JORDAN: The Pro story is interesting because it's not just one thing — it's an ecosystem play. QuoteCenter, the SRS acquisition, GMS, purchase cards — they're stitching all of this together so a Pro can basically source everything through the Home Depot family instead of shopping around. Ann-Marie Campbell said 90% of stores closed a sale through SRS's catalog in the last 12 months.ALEX: That's a real flywheel if it keeps compounding. And on the digital side — online comp sales grew 11%, the fifth straight quarter of double-digit growth. They also launched Express Delivery nationwide this month — three-hour delivery on tens of thousands of products, with most actually arriving in under an hour.JORDAN: That's a meaningful shift. Delivery lead times are down about 45% over the last 18 months. For a company built on people driving to an orange box store, leaning this hard into fast delivery — including big and bulky items and even next-day appliance delivery in some markets — signals they're taking the fight to online-only competitors pretty seriously.ALEX: Now, let's talk about the part of the call that generated the most back-and-forth — gross margin and tariffs.JORDAN: Right, so this is the one investors were parsing closely. Home Depot received $730 million in IEEPA tariff refunds this quarter, and $685 million of that flowed through and reduced cost of goods sold. That gave gross margin a roughly 145 basis point boost.ALEX: But — and this is the nuance — that benefit was largely offset by rising costs elsewhere. About 60 basis points of pressure from fuel, energy, and other input costs, plus another 60 basis points from a mix shift tied to the GMS acquisition. Net-net, grossThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Gilead Sciences' second quarter 2026 results — and Jordan, this is a big one.JORDAN: It really is. Big numbers, big acquisitions, big pipeline news.ALEX: Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good to have that out there. Okay, let's talk numbers. Gilead's base business — that's total product sales excluding the COVID drug Veklury — came in at $7.6 billion, up 10% year-over-year. That's their strongest second-quarter growth in three years.ALEX: And it's broad-based too. HIV sales were up 12% to $5.7 billion, Trodelvy in oncology up 26%, and Livdelzi in liver disease more than doubled. On the back of that, management raised full-year HIV growth guidance to 9-10%, up from 8%.JORDAN: The headline stat for me was PrEP — that's HIV prevention. Quarterly PrEP sales topped $1 billion for the first time, doubling year-over-year, putting that business on a $4 billion annual run rate. Yeztugo, their twice-yearly injectable, is now the leading option for new PrEP starts and even leads the switch market after just four quarters on the market.ALEX: And they shared something pretty striking — more than 70% of Yeztugo patients are coming back for their second injection at six months, meaning they get a full year of protection. That persistency rate is apparently well above anything else in the category.JORDAN: Now, EPS is where things get messy — but for a good reason. Non-GAAP diluted EPS was actually negative $6.75 for the quarter.ALEX: Wait, negative? That sounds alarming.JORDAN: It sounds alarming, but it's really an accounting story. Gilead closed three acquisitions this quarter — Arcellx, Tubulis, and Ouro Medicines — totaling about $11.2 billion in acquired R&D expense, which under accounting rules gets taken as a hit all at once. Strip that out, along with a one-time non-cash revenue item, and EPS was actually $2.27 for the quarter — up about 13% year-over-year on an apples-to-apples basis. That's outpacing revenue growth, which tells you there's real operating leverage in this business.ALEX: Right, and full-year guidance reflects that same split — they're now guiding to $30.1 to $30.4 billion in total product sales, raised from prior guidance, but full-year EPS on a GAAP-ish basis is guided negative because of those acquisition costs. Excluding the deal noise, full-year EPS guidance is $8.50 to $8.85, actually raised slightly on the low end.JORDAN: So the deals are the real story of the quarter, strategically speaking. Let's unpack them. Arcellx gives Gilead full ownership of anito-cel, their multiple myeloma cell therapy — that's five months from its PDUFA date, so a launch is coming. Tubulis brings an antibody-drug-conjugate platform, and there's already exciting early data on GS-8824 in ovarian cancer — 61% response rate in a tough, pretreated population.ALEX: And on the existing portfolio side, it wasn't just an acquisitions quarter. Trodelvy got approved for first-line metastatic triple-negative breast cancer, roughly doubling its addressable patient population. Livdelzi, the liver disease drug, posted positive phase III data that could expand its use. And they launched Hepcludex, the first-ever approved treatment for chronic hepatitis D.JORDAN: One thing that jumped out in the Q&A — an analyst pushed CEO Dan O'Day on whether Gilead still cares about diversifying away from HIV, since HIV remains such a dominant chunk of revenue. His answer was basically "yes, but we're doing it two ways" — diversifying within HIV itself with new dosing options, daiThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: ENERGY (https://betafinch.com/groups/ENERGY)──────────**WELCOME BACK TO BETA FINCH**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, bringing you the numbers and the narrative behind the companies moving markets. I'm Alex.JORDAN: And I'm Jordan. Today we're diving into EOG Resources' second quarter 2026 results — and Alex, this one's got some genuinely fun stuff in it, including oil wells in the UAE.ALEX: We'll get there. But first, the disclaimer, because we always start with it: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good, glad that's out of the way. Okay Alex, break down the numbers for us — this was apparently a record quarter for EOG.ALEX: It really was. Adjusted earnings per share came in at $5.70, adjusted cash flow per share hit $8.29, and free cash flow was $2.8 billion — all record levels. CEO Ezra Yacob credited robust oil prices, but he was careful to frame this as more than just a commodity tailwind — he called it "consistent, high-quality execution."JORDAN: And the shareholder return story backs that up. They returned just over $1.8 billion to shareholders in the quarter — $540 million in dividends, $1.3 billion in buybacks. They've now got $11.7 billion left on the repurchase authorization, and they're reiterating that commitment to return at least 70% of annual free cash flow in 2026.ALEX: The balance sheet numbers are what really stood out to me. $4.9 billion in cash, net debt of just $3 billion, and — this is the eye-popping one — a WTI breakeven price below $50 a barrel for the whole 2026 program. That's a lot of cushion.JORDAN: Twenty-eight years without a dividend cut or suspension, too. That's not a typo — that track record spans multiple oil crashes, COVID, you name it.ALEX: Right, and guidance-wise, they're holding capex steady at $6.5 billion for the year, targeting 5% oil production growth and 14% total production growth. Let's talk strategy now, because the headline story this quarter was really about exploration — specifically, international exploration.JORDAN: Yeah, this was the most interesting part of the call for me. EOG drilled two one-mile wells in the UAE with ADNOC, and in the first 30 days those wells averaged over 25,000 barrels of oil per well — flowing naturally, not even on artificial lift yet.ALEX: And Keith Trasko, their SVP of Exploration, said the geologic analog they're using is the Eagle Ford — similar rock type, similar product mix, similar GOR and API gravity. So this isn't some totally unknown formation to them; it rhymes with a play they've drilled for over a decade.JORDAN: Executives were pretty clear-eyed about it too — Ezra called it early innings, a 900,000-acre concession, three-year exploration phase, and ADNOC has an option to back in down the line. They're not rushing toward a final investment decision.ALEX: There was also a really human moment in the Q&A about the Iran conflict's impact on operations. Ezra said that despite intermittent operations in Bahrain due to the conflict, the crisis actually became — his words — "an opportunity to stress-test the relationship with our partners," and that communication with ADNOC and Bapco had been transparent throughout.JORDAN: Domestically, the other big reveal was a new Austin Chalk "sweet spot" in Lavaca County, Texas — 60,000 net acres leased at around $1,200 an acre, adjacent to their Eagle Ford position. Twelve wells drilled so far showing sub-one-year payouts and returns over 100% at $65 WTI.ALEX: Jeff Leitzell, the COO, framed that as roughly a full extra year of drilling inventory for their San Antonio division. And it's a good example of their broader theme this quarter — using their in-house techniThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: ENERGY (https://betafinch.com/groups/ENERGY)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Duke Energy's second quarter 2026 results. Duke's the largest regulated utility fleet in the country, so this one's worth paying attention to.Before we dive in, a quick note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Alright, let's get into the numbers. Duke posted adjusted EPS of $1.43 for Q2, up nicely from $1.25 a year ago. Reported EPS came in at $1.38.ALEX: And the growth story here is pretty straightforward — electric utilities and infrastructure added $0.15 year-over-year, driven by customer growth and all the infrastructure investment they're pouring into their service territories. Gas utilities were roughly flat, which management chalked up to it just being a seasonally quiet quarter.JORDAN: Worth flagging — favorable weather helped too. Cold first quarter, hot second quarter, and Duke's generating fleet cashed in on that demand. CFO Brian Savoy actually said they might reinvest some of that weather upside back into their generating facilities in the back half of the year. That's a smart move — banking some of the windfall into asset reliability rather than just letting it flow straight to the bottom line.ALEX: Big picture, they reaffirmed full-year guidance of $6.55 to $6.80 in adjusted EPS, and they're sticking with their long-term target of 5% to 7% EPS growth through 2030. But here's the headline: management said they're increasingly confident they'll land in the top half of that range starting in 2028.JORDAN: That 2028 timing matters. That's when the big economic development projects — mainly data centers — start ramping up under their electric service agreements, or ESAs. Duke's now signed 7.8 gigawatts of these agreements, and they're targeting the full 15.4 gigawatt pipeline to convert by the first half of 2027.ALEX: Let's talk about the capital side because it's massive. Duke's running what they call the industry's largest regulated capital plan — over a billion dollars a month going into the ground. And on top of the existing five-year plan, they flagged another $5 to $10 billion of potential upside, mostly tied to new generation and transmission needs in Indiana and Florida as more of these large-load contracts get signed.JORDAN: That's a real growth lever, but I want to highlight something else — the regulatory side. Duke reached a settlement in North Carolina on their DEC rate case: 9.8% ROE, 53% equity layer, and they kept an earnings sharing mechanism that lets them earn up to 10.3% ROE if they outperform. They're now trying to reach a similar settlement for the DEP case, with a hearing scheduled and orders expected by mid-November on both.ALEX: Constructive regulatory outcomes are the backbone of the utility thesis, and Duke's track record here is strong. They also rolled out something called the Customer Protection Plus commitment — basically formalizing that large data center customers pay their own way and don't stick existing ratepayers with the bill. That's a direct response to the affordability concerns we're hearing across the sector.JORDAN: Speaking of affordability — that came up a lot in the Q&A, especially around Indiana. There's been real political pressure there given rising costs generally, and analysts pushed CEO Harry Sideris on whether Duke might use a GENCO-type structure to help finance large-load generation separately. His answer was essentially: we've looked at it before, didn't need it then, but we're open to revisiting it as these big contracts get signed.ALEX: The nuclear conversation was interesting too. Duke's doing about 300 megawatts of upraThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────WELCOME TO BETA FINCH, YOUR AI-POWERED EARNINGS BREAKDOWNALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Disney's fiscal third quarter, reported August 5th. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And there's a lot to get into here, Alex, because this was genuinely a strong quarter for the House of Mouse.ALEX: It really was. Let's start with the headline numbers. Total segment operating income was up 21% year-over-year, company-wide revenue grew 7%, and the star of the show was the Experiences segment — that's parks, cruises, and consumer products — which hit a record $10 billion in quarterly revenue, up 10% from last year.JORDAN: And it wasn't just revenue growing because people are paying more to walk through the gates. Global guest counts were up 4%, domestic park attendance was up 3%, and per-capita spending was up another 4% on top of that. So you've got volume and pricing both moving in the right direction at the same time.ALEX: Which CEO Josh D'Amaro made a point of highlighting — he said flat out they're not "discounting their way to volume growth," even though they rolled out things like after-2pm pricing at Walt Disney World and Anaheim resident discounts. Those are targeted promotions to specific customer segments, not a sign of underlying weakness.JORDAN: Right, and CFO Hugh Johnston backed that up when analysts pushed on it — international attendance in Shanghai and Hong Kong has been soft due to a weaker Asian consumer, but domestic tourism and local resident growth more than offset it. They actually raised full-year guidance for Experiences operating income to the high end of their previous high-single-digit growth range.ALEX: Now let's talk content, because this quarter had a bit of a mixed bag theatrically. Toy Story 5 crossed a billion dollars at the global box office — huge win. But The Mandalorian and Grogu and the live-action Moana both underperformed expectations.JORDAN: And here's the interesting part — management basically said, "so what?" Hugh Johnston called the film business "a portfolio game" and pointed out that even when a movie doesn't crush it theatrically, the IP still pays off elsewhere. The Mandalorian and Grogu drove retail sales and traffic to the Millennium Falcon attraction at the parks. That's the whole "Disney flywheel" thesis — one story, monetized across theaters, streaming, parks, and merchandise.ALEX: Which, by the way, Toy Story is the poster child for — five films, over $4 billion in box office, 2 billion-plus hours streamed, four theme park lands, nineteen attractions, two hotels. That's a level of cross-platform integration that's genuinely hard for competitors to replicate.JORDAN: And they got a nice tailwind they didn't even make — Sony's Spider-Man had a record-breaking opening weekend this past weekend, and Josh was quick to point out Disney still owns a piece of that character's value through consumer products, parks, and streaming even though Sony released the film. Nice reminder that IP value doesn't always require Disney to foot the production bill.ALEX: Let's shift to streaming, because that's where a lot of the long-term story is being written. SVOD operating margin came in at 13% this quarter, and they're still targeting double-digit margins for the full fiscal year. Big milestone too — Hulu subscribers can now link profiles and manage everything through the Disney+ app, which is a step toward that "One Disney" unified experience.JORDAN: And the announcement that got people talking this morning was the TikTok distribution deal. The idea is to bringThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex.JORDAN: And I'm Jordan. Today we're digging into Deere & Company's third quarter fiscal 2026 results — big green tractors, big infrastructure equipment, and a business that's basically riding two different economic cycles at once.ALEX: Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good, let's get into the numbers. Alex, what jumped out at you?ALEX: The headline is Deere beat expectations pretty handily. Net sales and revenue up 5% to $12.6 billion, equipment operations sales up 6% to $11 billion, net income of $1.38 billion, or $5.10 a share. And that 14.4% operating margin for equipment operations is genuinely strong given how choppy the ag market is right now.JORDAN: Right, and that's really the story of this quarter — a tale of two businesses. Production & Precision Ag, their big-tractor and combine segment, was actually down 6% year-over-year to $4 billion, with margins around 13.2%. That's the segment feeling the ag downturn most directly.ALEX: But then you flip to Small Ag & Turf — up 12% to $3.4 billion with an 18.4% margin — and Construction & Forestry, up 18% to $3.6 billion with a 12.1% margin. Those two segments are basically carrying the company through the ag trough.JORDAN: That diversification point came up again and again on the call. Management kept saying it — while big ag equipment is struggling, construction and the smaller ag/turf business are picking up the slack. It's a nice illustration of why a diversified portfolio actually matters in a cyclical industry.ALEX: Let's talk guidance, because they actually raised the full-year outlook despite trimming some segment numbers. Full-year net income guidance moved up to $4.75 to $5 billion, and operating cash flow guidance improved to $5 to $5.5 billion.JORDAN: But within that, Production & Precision Ag guidance came down — now expecting sales down about 10% for the year, with margin guidance narrowed to 11-12%. That's mostly South America and Europe softness. South America specifically is now guided down 15-20% for the year, driven by high interest rates and elevated fertilizer costs squeezing farmer economics.ALEX: Meanwhile Small Ag & Turf guidance actually went up — margin guide raised to 14.5-15.5% — and Construction & Forestry held its roughly 20% sales growth guide with margins tightened to 10.5-11.5%. Construction is genuinely firing on all cylinders right now: data centers, infrastructure, road building.JORDAN: One thing worth flagging for listeners — tariffs were a huge theme on this call. Deere now expects about $1.1 billion in direct tariff expense for the year, offset partially by $382 million in IEPA refunds recognized so far. CFO Brent Norwood said net tariff exposure this year is around $750 million, but he flagged that it'll actually step up to roughly $1 billion next year as the refund benefit doesn't repeat.ALEX: That's an important nuance — investors hear "tariff relief" and assume it's all good news, but the mechanics here mean next year could actually be a modest headwind, not a tailwind.JORDAN: The other big storyline was the model year 2027 early order programs — these are essentially pre-orders dealers and farmers lock in ahead of the season. Deanna Kovar, who runs the ag and turf business, said combined planter and sprayer orders are running up mid-single digits versus last year.ALEX: And that's a meaningful signal because management explicitly said they view 20This episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Cisco's fiscal Q4 and full-year 2026 results — and Jordan, this one's a doozy.JORDAN: Record year across the board. I'm ready.ALEX: Before we dive in — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good, now let's get into it. Cisco just closed out fiscal 2026 with revenue over $63 billion, up 12% for the year. But the real headline is Q4 — record revenue of $17.3 billion, up 18% year-over-year, and product revenue up 24%.ALEX: And it's not just top-line. Non-GAAP EPS grew 23% in the quarter, 14% for the full year — so earnings actually outgrew revenue. That's the kind of operating leverage investors love to see.JORDAN: Right, and they backed it up with cash returns — $3.2 billion returned to shareholders in Q4 alone, $12.7 billion for the year, which was basically 99% of free cash flow. Fifteenth consecutive year of dividend increases too.ALEX: So what's driving all this? One word CEO Chuck Robbins used a lot: "super cycle." He's talking about a networking super cycle fueled by agentic AI. Product orders overall were up 35% year-over-year, and hyperscale orders — meaning the big cloud players — grew triple digits.JORDAN: That AI infrastructure number is wild. Cisco took $4 billion in AI orders from hyperscalers in Q4 alone, bringing the full-year total to $9.3 billion — that's about 4.5 times what they did the year before. And for fiscal 2027, they're guiding to $7.5 billion in actual AI infrastructure revenue.ALEX: Worth noting — orders and revenue aren't the same thing. These are big, lumpy, non-linear deals that get placed way ahead of when they actually ship and get recognized as revenue. That's an important nuance analysts pressed on during Q&A.JORDAN: They also talked about this "scale-across" opportunity — basically connecting multiple data centers together as AI models outgrow the power and space of a single facility. Cisco says traffic from that kind of AI-driven interconnect could be 14 times what traditional data center traffic looked like. They've already landed three separate hyperscaler design wins for their new P200 chip system aimed at exactly that use case.ALEX: And it's not just hyperscalers. Enterprise product orders accelerated to 21% growth, public sector orders were up 30%, and campus networking — which is basically the corporate office refresh cycle — grew 20%, with Wi-Fi 7 now over half of wireless orders.JORDAN: Security was a bright spot too — the whole security portfolio including Splunk grew double digits, firewall orders were up over 30%. Though CFO Mark Patterson did flag that some of that 14% revenue growth in security got a boost from a few larger, longer-duration on-prem Splunk deals — so temper expectations there slightly.ALEX: One thing that stood out to me in the Q&A: analysts kept asking, "Is this the peak of the cycle?" And Chuck Robbins pushed back hard, saying they're seeing convergence of multiple tailwinds at once — AI buildouts, a looming end-of-support product refresh they're calling "Mythos," and even early quantum-readiness spending.JORDAN: Yeah, that Mythos comment was interesting — he described a manufacturing CEO's team calling in saying essentially "we have no choice, we have to upgrade equipment that's past end of life." Robbins framed it like the early days of cybersecurity spend — something that stops being optional and just becomes a line item companies find budget for.ALEX: Now, not everything was pure upside. Gross margins came in at 66.3%, down 210 basis points year-over-year, mostly due to higher hardware mix and memory costs. Management said to expect continued gross margin pressure iThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────**BETA FINCH: SALESFORCE Q2 FY2027 EARNINGS BREAKDOWN**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.JORDAN: And I'm Jordan. Today we're diving into Salesforce's fiscal Q2 2027 results — and this one came with a genuinely wild product announcement dropped mid-call.ALEX: Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Okay, so let's start with the headline: right before this call, Marc Benioff and Anthropic's Dario Amodei went on CNBC together to announce "Claudeforce" — a joint product combining Anthropic's Claude with Salesforce's CRM data and workflows.ALEX: Right, and the pitch is basically: Claude brings the reasoning and the interface, Salesforce brings the trusted data, permissions, and business logic underneath it. Benioff's framing was "one plus one equals three."JORDAN: It's a notable pairing given all the "SaaSpocalypse" chatter — the idea that AI agents would just cannibalize traditional software companies. Benioff spent a huge chunk of this call directly pushing back on that narrative.ALEX: And he had numbers to back it up. Net new annual contract value growth — basically new bookings — was the strongest it's been in four years. Attrition was near an all-time low. Contract lengths got longer across every segment.JORDAN: Let's get into the actual financials, because the quarter itself was solid. Revenue came in at $11.35 billion, up 11% year-over-year, above the high end of guidance. Subscription and support revenue was $10.82 billion, up 12%.ALEX: Current remaining performance obligations — CRPO, which is a good forward-looking bookings indicator — accelerated to 14% growth in constant currency, a point ahead of guidance.JORDAN: Free cash flow was the standout for me: $1.1 billion, up 81% year-over-year. Non-GAAP operating margin held at 34.1%.ALEX: And on the AI-specific numbers — Agentforce, their AI agent product, hit $1.5 billion in ARR. Bookings for their premium AI bundles more than doubled quarter-over-quarter. Agent usage through API-style calls surged sixfold.JORDAN: Sixfold in a single quarter is a big number. And COO Miguel Milano added some texture in Q&A — bookings for Agentforce roughly doubled year-over-year, they added 2,000 new paying customers into production, up 70% quarter-over-quarter.ALEX: They also raised full-year guidance — about $300 million in constant currency, split between organic growth and an expected contribution from two pending acquisitions, Contentful and the customer-service AI company Fin, both expected to close soon. New FY2027 revenue guide is $46.1 to $46.4 billion.JORDAN: Now, the Claudeforce reveal aside, I want to flag something structural that came up a few times: Salesforce is explicitly moving toward what they're calling "headless" delivery and outcome-based pricing.ALEX: Meaning instead of just charging per user seat, they want to meet customers with flexible pricing — consumption-based, credits, or even tied to business outcomes, like "we generated you more revenue, so we take a cut."JORDAN: Milano gave a specific example — a digital platform customer whose AI agent usage grew 14x in a quarter, and Salesforce is now negotiating either a $40 million outcome-based deal or an unlimited usage agreement. That's the kind of expansion story investors want to hear, because it suggests real pricing power beyond the traditional seat model.ALEX: There was also a fun anecdote in the call — Ohalo's CEO David Friedberg joined as a guest and talked about how he almost built his own CRM instead of buying Salesforce, then ended up standing the whole thing up in under a month using Claude and Cursor alongside a Salesforce engineer. HiThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)──────────Welcome to Beta Finch, your AI-powered earnings breakdown of the companies moving the markets. Let's get into Caterpillar's second quarter.ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, joined as always by Jordan, and today we're digging into Caterpillar's Q2 2026 results — and folks, this is a big one. But before we dive in, quick reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And it's a good quarter to have that disclaimer front and center, Alex, because the numbers here are eye-popping. Caterpillar just posted $20.5 billion in sales and revenues — up 24% year-over-year. That's the first time in company history they've cracked $20 billion in a single quarter.ALEX: A genuine milestone. And it wasn't just the top line — adjusted profit per share came in at $8.17, up 73% from last year. CEO Joe Creed called it out as a record, and honestly, the whole print beat expectations across the board.JORDAN: What really stands out to me is the backlog. It grew sequentially by $9 billion to $72 billion total — that's up 92% versus a year ago. And all three primary segments — Construction Industries, Resource Industries, and Power & Energy — contributed to that growth. This isn't a one-segment story.ALEX: Right, and that Power & Energy segment is the one everyone's buzzing about because of the AI and data center angle. Sales to users in power generation grew 72% — driven by demand for large gen sets and turbines going into data centers.JORDAN: It's wild — they're literally restarting a discontinued product line for this. They stopped making their 10-megawatt medium-speed gas reciprocating engine back in 2022, and now they're bringing back about 1.5 gigawatts of capacity because customers are asking for more units. Shipments start in Q4.ALEX: And on the call, an analyst pushed Creed on whether that demand has real staying power out to 2028, 2029, 2030 — given how much AI capex speculation is out there. Creed's answer was pretty direct: "No one is slowing down at the moment. In fact, if we can get more units out, they're asking us to give them more units." They're already taking orders into 2029 and 2030.JORDAN: And it's not just data centers propping this up — that's the part I found reassuring. Oil and gas backlog is nearly double what it was a year ago, mostly gas compression demand. So even if the AI narrative cools at some point, there's a broader base under this Power & Energy growth story.ALEX: Let's talk Construction Industries too, because that segment had its own headline moment — sales up 35% to $8.3 billion, sixth straight quarter of sales-to-users growth. A lot of that was rental fleet loading, including this new "Major Projects" joint venture with dealers — basically a national rental fleet aimed at massive infrastructure and data center builds.JORDAN: Margins there were strong too — 23.3%, up 320 basis points. Resource Industries also chipped in with 20% sales growth, helped by mining demand for copper and gold, plus they closed the Skycatch acquisition in July — that's AI-powered spatial data tech for mining operations.ALEX: Now, we can't ignore tariffs — they came up a lot on this call. CFO Kyle Epley said the company got a $392 million benefit from IEEPA tariff recoveries this quarter, and actual tariff costs came in lower than expected, around $400 million versus the $700 million they'd guided to in April. For the full year, they now expect about $2.2 billion in tariff costs, the low end of their prior range.JORDAN: That's a meaningful swing, and it's part of why margins beat — adjusted operating profit margin hit 21.9%, up 430 basis points year-overThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL)──────────**BETA FINCH — Booking Holdings (BKNG) Q2 2026**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.JORDAN: And I'm Jordan. Today we're digging into Booking Holdings' second quarter 2026 results.ALEX: Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good to have that on record. So, Alex, headline here: Booking beat guidance across the board again.ALEX: Yeah, and in a genuinely messy environment too. Room nights grew 5%, gross bookings up 9% — or 8% constant currency — revenue up 8%, and adjusted EBITDA hit about $2.6 billion, up 9%. All of that came in above the high end of their own guidance.JORDAN: The EPS number is the one that jumps out to me — $2.54, up 15% year-over-year. That's growing faster than EBITDA, and a big chunk of that is financial engineering: a 6% reduction in share count from buybacks.ALEX: Right, and they weren't shy about it — $3.7 billion in repurchases this quarter alone, $7.4 billion for the first half at an average price around $173 a share. Plus they returned $4.1 billion total to shareholders, a record quarter for capital returns.JORDAN: Now here's the context that matters — this wasn't a clean quarter. CFO Ewout Steenbergen was pretty direct about the Middle East conflict weighing on long-haul international travel, airline capacity, and flight prices. That hit international room nights, which only grew "slightly," versus domestic room nights growing high single digits.ALEX: And flights specifically decelerated to just 4% growth, rental cars were soft too. But management framed that as almost entirely exogenous — Steenbergen actually said their flights business is outperforming the broader airline industry, which was hurt worse by the same dynamics.JORDAN: Let's talk regions for a second, because there's a real divergence. Europe grew mid-single digits, Asia mid-single digits domestically hit especially hard by Strait of Hormuz exposure, and the U.S. — high single digit room night growth, which CEO Glenn Fogel was clearly proud of.ALEX: He called it out multiple times — said the U.S. has been a multi-year investment priority and they're "doing something right." Direct channel growth in the U.S. continues too, which matters because it's cheaper customer acquisition.JORDAN: Speaking of which, can we talk about the SEO comment? That was one of the more candid moments on the call. An analyst pushed on whether AI Overviews in Google search are pressuring organic traffic, and Fogel basically confirmed it — said the AI overview changes at Google "definitely put some pressure on SEO."ALEX: But he was quick to add SEO was always a small slice of the business, and their direct booking mix held steady in the mid-60% range. Their read is that people who used to arrive via SEO are just finding them another way — the absolute direct number kept growing.JORDAN: The AI thread ran through basically the entire Q&A. Multiple analysts asked variations of "is AI actually moving the needle yet?" And the honest answer from management was — not really, not yet, at least not visibly.ALEX: Steenbergen gave a specific number here that I think listeners should note: traffic coming from large language models, both paid and organic, is still "significantly below 1%" of room nights, and it hasn't moved much in recent quarters.JORDAN: So despite all the AI-powered discovery rollouts — Booking.com's new inspiration search, Priceline's Penny assistant, Agoda's gallery view — the actual booking impact is still tiny. Management's line was essentially "we're positioned well for whenever this shifts, but it hasn't shifted yet."ALEX: Where AIThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────Welcome to Beta Finch, your AI-powered earnings breakdown of the companies moving the market. I'm Alex, and I'm here with Jordan, and today we're digging into AppLovin's second quarter 2026 results.ALEX: Before we get into it, quick disclaimer — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And this one's actually a pretty interesting story, Alex, because it's a rare miss for AppLovin.ALEX: Right, so let's start with the numbers. Revenue came in at $1.92 billion for the quarter, up 53% year-over-year, but that landed just below the midpoint of guidance. Adjusted EBITDA was $1.61 billion, up 58% year-over-year with margins expanding about 300 basis points — but again, just under the guided range.JORDAN: And CEO Adam Foroughi was pretty direct about it right out of the gate. He basically said, "we fell short of our own standard." Which, for a company that's been beating and raising for something like twelve straight quarters, is notable.ALEX: So what actually happened? It comes down to their AI models. AppLovin's whole growth engine is model performance — better models mean advertisers can spend more profitably at their target return on ad spend. This quarter, the pace of model improvement was just lighter than usual. The "next step up," as Foroughi called it, landed just after the quarter closed instead of during it.JORDAN: Which is really a timing issue, not a demand issue. That distinction matters a lot here. He pointed out that MAX, their publisher marketplace, grew double digits quarter-over-quarter, and their share of ad inventory stayed consistent. So advertisers weren't pulling back — the models just didn't get their usual mid-quarter boost.ALEX: And now that the new model is live in Q3, they're saying the business has already re-accelerated.JORDAN: The other big storyline is the consumer business — that's their e-commerce and web advertising push. Advertiser spend hit a record, 28% above Q4 2025 levels, and Q4 is normally their seasonal peak. Growing past peak-season levels in what's usually a slow quarter is a pretty strong signal.ALEX: Right, and CFO Matt Stumpf made clear the higher costs this quarter were deliberate — they're investing in more complex, compute-hungry model architectures, and that spending is tied directly to the performance gains they're now seeing in Q3.JORDAN: There's also a fun detail buried in there — they officially opened their ad platform to the public in June under the AppLovin Ads Manager name. Remember, this used to be branded AXON, then it went back to AppLovin.ALEX: Foroughi joked they "can't get rid of the name AppLovin" — everyone just kept calling them that no matter what they rebranded to.JORDAN: What stood out to me in the Q&A was the partnership strategy. They're now doing deals with companies like attribution and analytics platforms — Triple Whale got called out by name — to funnel in mid-market advertisers in a targeted way, rather than just opening the floodgates to long-tail signups.ALEX: Which makes sense given where their model sophistication is. Foroughi was pretty candid that gaming is a mature, well-oiled machine at this point — new games hit their return targets almost immediately — but e-commerce is still early. Small shops don't always have the budget or the creative assets to make it work yet. Mid-market is the sweet spot right now.JORDAN: One thing worth flagging for listeners — there was a housekeeping item. AppLovin confirmed the SEC concluded its previously disclosed voluntary inquiry with no recommended action. So that overhang is officially resolved.ALEX: Also notable: free cash flow came in at $863 million, lower than normal due to timing of international tax and iThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: CHIPS (https://betafinch.com/groups/CHIPS), AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)──────────**BETA FINCH — AMD Q2 2026 EARNINGS BREAKDOWN**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Advanced Micro Devices — AMD — and their second quarter 2026 results. Jordan, this one's a big one.JORDAN: It really is. Record revenue, and the guidance for next year is honestly kind of stunning. Let's get into it.ALEX: Before we do — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good to have that up front. Okay, let's talk numbers.ALEX: AMD posted revenue of $11.5 billion for Q2, up 50% year-over-year and 13% sequentially. That's their sixth straight quarter of greater-than-30% growth, which is a pretty remarkable streak.JORDAN: And the story underneath that number is really about data center. It's now 58% of total revenue, up from 42% a year ago. Data center segment revenue was $6.7 billion, more than doubling year-over-year. Split that in two: server CPUs — that's EPYC — grew over 70% in both cloud and enterprise, fifth consecutive quarter of record server CPU revenue. And Instinct, their AI accelerator line, more than doubled.ALEX: Profitability kept pace too. Gross margin hit 56%, up over 200 basis points year-over-year. Operating income was $3.1 billion, a 27% operating margin. And non-GAAP diluted EPS grew about 82% year-over-year — meaningfully outpacing revenue growth.JORDAN: That's the operating leverage story playing out in real time.ALEX: Client and gaming was more mixed. Client — that's PCs — grew 23% to $3.1 billion on record mobile processor sales and strong commercial Ryzen PRO adoption. But gaming dropped 31% to $779 million, mostly semi-custom console revenue fading late in that console cycle, plus some pricing pressure on graphics cards from component costs.JORDAN: Embedded was a bright spot too — up 19% to $977 million, their strongest growth in three years, with networking and defense customers leading the way.ALEX: Now let's talk strategy, because this is where CEO Lisa Su really leaned in. The headline announcement was Helios — their new rack-scale AI platform combining EPYC Venice CPUs, MI450 GPUs, networking, and their ROCm software stack.JORDAN: And the customer list here is the story. They already had multi-generation, gigawatt-scale commitments with OpenAI and Meta. Now add a brand-new strategic partnership with Anthropic — up to 2 gigawatts of MI450 GPUs, with the first gigawatt deploying in early 2027. There's also a joint engineering piece where Anthropic's Claude models help optimize workloads for AMD's chips.ALEX: And Microsoft is expanding its footprint too, deploying Helios at scale on Azure for frontier model inferencing.JORDAN: What stood out to me is how much AMD raised its own long-term targets. They now expect the AI accelerator market to hit roughly $1.4 trillion by 2030, and the server CPU market around $220 billion. Combined, they're calling the total high-performance and AI computing market close to $2 trillion by 2030.ALEX: And Lisa Su said flatly that AMD is tracking materially ahead of the long-term model they laid out at last November's Analyst Day — revenue growth well above their prior 35% target, and EPS expected to "significantly exceed" their $20 target.JORDAN: That's a big statement to make less than a year after setting those targets.ALEX: Let's get into guidance. For Q3, AMD is guiding to about $13 billion in revenue, plus or minus $300 million — that's 41% year-over-year growth at the midpoint. Gross margin guided at approximately 56%.JORDAN: And looking further out, thThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: CHIPS (https://betafinch.com/groups/CHIPS)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, coming to you fresh off Applied Materials' fiscal third quarter 2026 report. I'm Alex, joined as always by Jordan. Before we dive in — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And this was a big one, Alex. Applied Materials just posted the highest quarter-over-quarter revenue growth in company history.ALEX: Let's start with the numbers. Q3 revenue came in at $9.1 billion — up 15% sequentially and 25% year-over-year. Non-GAAP gross margin hit 50.4%, and operating margin expanded to a record 34%. EPS was $3.50, up 41% year-over-year.JORDAN: And it's not slowing down — Q4 guidance is $10.25 billion, plus or minus $500 million, which would be up 51% year-over-year. EPS guide of $4.02, up 85% year-over-year. Those are eye-popping growth rates for a company this size.ALEX: The story here is really AI infrastructure. CEO Gary Dickerson framed it as two races happening at once: a race for technology leadership and a race for capacity. Chipmakers can't build fast enough to meet AI demand.JORDAN: Right, and Applied's positioned right at the intersection — leading-edge foundry logic, DRAM, and advanced packaging. Management said those three areas represent roughly 80% of wafer fab equipment growth in both 2026 and 2027. DRAM revenue alone grew 52% year-over-year, and packaging revenue is now expected to grow more than 70% for the calendar year.ALEX: What stood out to me was the visibility. CFO Brice Hill said some customers are now giving them rolling eight-quarter forecasts, and in some cases conversations stretching out to 2030.JORDAN: That's unusual for this industry, which has historically been pretty cyclical and choppy. Longer-term agreements mean Applied can plan supply chain and manufacturing capacity with much more confidence. They're actually building toward doubling their quarterly system output by 2028.ALEX: Doubling. That's a serious bet on sustained demand.JORDAN: And to be fair, management was careful to clarify that's a capacity statement, not a revenue forecast — an analyst pushed on that directly during Q&A. But it tells you how confident they are that this isn't a short-term spike.ALEX: Let's talk strategy for a second — the EPIC Center. Applied is opening a new R&D facility in Silicon Valley where they co-locate with customers and partners to speed up innovation. They've now got 11 announced partners, including a new one this quarter — Broadcom — plus SCREEN and UC Berkeley.JORDAN: The logic is pretty simple: get designed into next-generation chip architectures earlier, and you capture more value and get better visibility into what customers actually need five, even ten years out. Gary Dickerson said some of these technology conversations go out a decade.ALEX: Now, gross margins were a hot topic in the Q&A — multiple analysts pressed on this.JORDAN: Yeah, a few different angles. One, why margins are guided roughly flat near-term despite all this growth — and the answer was ramp costs. They're hiring aggressively, over 1,500 people added this quarter alone in manufacturing and service support, and that creates a temporary headwind even as segment mix improves.ALEX: And two, this value-based pricing strategy Brice talked about. Essentially, Applied re-prices tools based on the value they deliver rather than just cost-plus, and that's added about 300 basis points to company gross margins over the last three years.JORDAN: Segment-level margins are already north of 55% in semiconductor systems, which is genuinely strong for an equipment maker. And services — Applied Global Services — had a great quarter tooThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: CHIPS (https://betafinch.com/groups/CHIPS)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown of the companies moving the market. I'm Alex.JORDAN: And I'm Jordan. Today we're digging into Analog Devices' fiscal Q3 2026 results — and Alex, this one's got a headline number that's hard to miss.ALEX: Before we get into it — quick reminder for everyone listening. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good. Now let's talk numbers. ADI just posted its first-ever $4 billion quarter — $4.02 billion in revenue, up 11% sequentially and 40% year over year. That's a big deal for a company this size.ALEX: It really is. And it wasn't just one segment carrying the load — growth was broad-based. Industrial was up 53% year over year, automotive up 16%, communications up a massive 84%, and even consumer, which has been the laggard, grew 6%.JORDAN: Communications is the one that jumps out to me. Data center now makes up 80% of that segment, and it grew over 100% year over year — both optical and power products doubled. That's the AI infrastructure story playing out in real numbers.ALEX: Right, and it flowed straight to the bottom line. Gross margin hit 72.5%, operating margin was 50%, and EPS came in at a record $3.45 — up 68% from a year ago.JORDAN: And the guidance for Q4 is even stronger. They're calling for $4.3 billion in revenue and gross margin jumping another 150 basis points to around 74% — levels we haven't seen since the 2022 peak. CFO Rich Puccio said that's coming from favorable mix, higher fixed-cost absorption, and — this caught my ear — price increases that haven't even fully kicked in yet.ALEX: Let's talk strategy, because CEO Vincent Roche spent a lot of time on what he called the "grid-to-chip" story. Basically, ADI isn't just selling chips that go inside AI servers — they're positioning themselves across the entire power chain, from the electrical grid all the way down to the processor.JORDAN: This is the part I found most compelling. Power, not compute, is now the bottleneck for AI. Roche made the point that going from 97% to 98% power conversion efficiency sounds trivial, but it cuts heat loss by roughly half — which matters enormously at data center scale. He even quantified it: their Empower acquisition, which lets them deliver power right into the processor package, can save about $30 million a year in a one-gigawatt data center.ALEX: And on the optical side, they're riding the shift from 800-gigabit to 3.2-terabit networking speeds, with optical circuit switching revenue expected to roughly double this year — and double again in 2027.JORDAN: The number that really stood out to me, though, was the SAM update — their addressable market for data center and energy by 2030 has more than doubled from what they projected just a year ago. That's not a small revision.ALEX: Now, the Q&A had some great moments. Analysts kept pushing on one question: how much of this growth is secular versus just a cyclical upswing? Vivek Arya from Bank of America basically asked, "if I annualize your Q4 guide, that implies 20%-plus growth into fiscal 2027 — is that real?"JORDAN: And Roche didn't shy away from it. He said he expects a "brisk growth year" in 2027, driven by the AI and defense super-cycles, Maxim acquisition synergies — which are on track to hit $1 billion-plus next year — and share gains across auto and consumer. He even said the analog industry, which historically grew mid-single digits, could sustain double-digit growth for years.ALEX: There was a great historical callback too — an analyst from Evercore asked him to compare this to the late-'90s telecom buildout, which also had big secular promises that ultiThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: ENERGY (https://betafinch.com/groups/ENERGY)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown for the companies moving the market. I'm Alex, joined as always by Jordan. Today we're diving into ExxonMobil's second quarter 2026 results — and this one's a doozy, because the backdrop was serious geopolitical disruption.Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Yeah, so let's set the scene. This quarter played out against the Middle East conflict, which knocked out roughly 10% of Exxon's upstream production. That's a huge hit operationally.ALEX: Right, but here's the headline — despite losing a tenth of their production, Exxon still posted $14.5 billion in earnings and $23.6 billion in cash flow from operations. That's industry-leading, disruption or not.JORDAN: It really speaks to the diversification strategy. Outside the Middle East, upstream production actually hit its highest level in over two decades. And chemical margins jumped about 180% quarter-over-quarter because their North American plants stepped in to cover the supply shortfall.ALEX: Let's talk Guyana, because this was the star of the Q&A. Production hit about 900,000 barrels a day gross, a fifth FPSO — that's a floating production vessel — set sail in June, and there's already talk of a ninth one being evaluated.JORDAN: The really interesting nugget is what CFO Neil Hansen called an "inflection point." Exxon has now recovered its full $55 billion investment in Guyana almost two years ahead of schedule. Under the contract structure, once you hit that recovery cap, more of the revenue flows straight to free cash flow instead of being funneled back into cost recovery.ALEX: So less volume growth going forward, but way more cash hitting the bottom line.JORDAN: Exactly — management was clear multiple times: "this is about value, not volume." They're projecting free cash flow from Guyana to roughly double by 2030 compared to 2025.ALEX: Now, refining — this is where it got really interesting given the Strait of Hormuz situation. CEO Darren Woods pointed out there's about 3 million barrels a day of refining capacity offline globally right now between the Strait closure, China halting exports, and Ukraine's strikes on Russian refineries.JORDAN: And Exxon's positioned well for that because of a decade of portfolio high-grading — they shed weaker refineries and invested in the strong ones. Their Gulf Coast operations ran at over 95% reliability this quarter and delivered record second-quarter diesel production.ALEX: One analyst pushed back a bit, though, noting refining earnings looked softer than some peers expected. Management chalked that up to volatility making margins hard to model in the moment, not any underlying operational issue.JORDAN: Specialty products was actually a quiet standout — record quarterly and first-half earnings, best-ever basestock margins. Their integrated value chain let them pivot around the crude supply disruptions better than competitors.ALEX: There was also a notable corporate move — Exxon officially redomiciled from New Jersey to Texas on July 1st, aligning their legal home with where they've actually operated for decades. Shareholders overwhelmingly approved it.JORDAN: And don't sleep on the cost story. Structural cost savings are now at $16.3 billion cumulative since 2019, on track for $20 billion by 2030. They're basically holding cash costs flat year-over-year despite inflation and continued growth spending — that's the discipline that's funded all this shareholder return.ALEX: Speaking of which — over $9 billion returned to shareholders this quarter through dividends and buybacks, plus more thanThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────WELCOME TO BETA FINCHALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Linde's second quarter 2026 results — ticker LIN, the industrial gas giant.JORDAN: Lots to unpack here, Alex. Records on one side, some real margin headaches on the other.ALEX: Exactly — but before we get into it, quick reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good to have that out of the way. So let's start with the headline numbers.ALEX: Linde posted record sales and EPS this quarter — both growing near double digits. Sales came in at $9.3 billion, up 9% year-over-year and 6% sequentially. EPS hit $4.50, up 10% from a year ago.JORDAN: And the backlog story is honestly the standout. It jumped by $1 billion to a record $8.1 billion, driven by a huge new electronics win in the U.S. — advanced semiconductor fabs, tied right into the AI hardware buildout.ALEX: CEO Sanjiv Lamba was pretty upbeat about that pipeline. He said he expects the backlog to still finish the year with an "eight handle" — meaning above $8 billion — even after they start up more than 20 projects worth about $1.3 billion in the back half.JORDAN: That's the growth engine working exactly as designed. But here's the catch — margins didn't cooperate this quarter.ALEX: Right, operating margins excluding cost pass-through actually declined about 30 basis points year-over-year. And management wasn't shy about saying they're "not satisfied" with that.JORDAN: The big culprit is their U.S. home care business — Lincare. CFO Matt White said the drag from that business is running about 30% higher than analysts had modeled — so more like $130-plus million of margin headwind this year, not the $100 million some were estimating.ALEX: That business has been fighting labor cost inflation and reimbursement policy changes. And interestingly, Sanjiv basically confirmed they're evaluating strategic options — could mean partial or full divestiture down the road.JORDAN: Which is a pretty significant signal. When a CEO says "we're evaluating the strategic fit, in part and as a whole," that's corporate-speak for "this could be sold."ALEX: Strip Lincare out, though, and the picture flips — Americas margins would've actually been up 20 basis points. So the core gases business is healthy; it's really this one legacy healthcare unit dragging things down.JORDAN: There's also a smaller mix effect — higher hard goods and equipment sales, especially in packaged gas and electronics equipment in Asia Pacific, which are lower-margin but were framed as a good sign of manufacturing recovery.ALEX: Let's talk end markets, because there's some genuinely interesting texture here. Electronics was the star — 18% growth year-over-year, driven by AI-related hardware demand and project startups.JORDAN: And there was a nugget most people probably missed — a Taiwan joint venture is investing roughly $800 million to build and operate air separation units and hydrogen production for new semiconductor and advanced packaging facilities. That's not even in the official backlog number.ALEX: Manufacturing was the fastest-growing industrial market, with aerospace alone contributing more than a third of that growth. And there's a real U.S. recovery narrative — package gas sales growing mid-to-high single digits, with hard goods up double digits.JORDAN: Then there was the Strait of Hormuz question, which came up a few times in Q&A. Linde's helium supply has been disrupted by the broader Middle East situation, but Sanjiv said the team has actually used the disruption to sign new long-term helium customers, leveraging diverse supply sources.ALEX: PriThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: ENERGY (https://betafinch.com/groups/ENERGY)──────────Welcome to Beta Finch, your AI-powered earnings breakdown of the companies moving the market.ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, here with Jordan, and today we're digging into Chevron's second quarter 2026 results. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And there's a lot to get into here, Alex. Chevron really came out swinging this quarter.ALEX: They did. Let's start with the headline numbers. Chevron reported earnings of $12.1 billion, or $6.11 per share. Adjusted earnings came in at $12 billion, or $6.06 a share. And CFO Eimear Bonner said that was up $9.2 billion versus last quarter.JORDAN: That's a massive jump quarter-over-quarter. And it wasn't just a one-line-item story — upstream earnings rose on higher realizations and liftings, downstream got a boost from stronger refining margins. Basically both engines were firing.ALEX: Right, and production tells the same story. Global upstream production grew more than 5% sequentially. In the U.S. specifically, they hit a new record of nearly 2.1 million barrels of oil equivalent per day, plus record refinery throughput over 1 million barrels per day.JORDAN: What stood out to me operationally was Tengizchevroil in Kazakhstan — production was up 170,000 barrels a day versus Q1. Management called it some of the best months they've ever had there. And they actually debottlenecked the third-generation plant, bumping nameplate capacity from 260,000 to 320,000 barrels of oil per day.ALEX: That's a real engineering win — low capital, high payoff. Let's talk cash and the balance sheet, because this is where things get interesting for shareholders. Cash flow from operations excluding working capital was almost $20 billion. Adjusted free cash flow was $15.4 billion.JORDAN: And they used that firepower to pay down over $8 billion in debt. Net debt to cash flow from operations is now just 0.6 times — that's a really strong balance sheet position.ALEX: They also hit a cost-cutting milestone six months early — $3 billion in annual run-rate structural savings since 2024, with over 70% of that coming from actual efficiency gains rather than just layoffs or one-time cuts.JORDAN: That's the more durable kind of savings too. Now, let's talk about the big strategic story here — the Hess acquisition just hit its one-year anniversary, and it sounds like it's going better than planned.ALEX: Way better. They captured 50% more synergies than originally targeted — $1.5 billion realized, six months ahead of schedule. And CEO Mike Wirth emphasized Guyana is a world-class asset that should extend high-margin oil growth into the 2030s.JORDAN: They're also finding upside in the Bakken they didn't fully appreciate before — drilling laterals 28% longer on average, maintaining production with one fewer rig. Sounds like Hess brought some operational know-how Chevron is now leveraging across the whole shale portfolio.ALEX: Now here's the part that really caught my attention — the power business. Jeff Gustavson, their New Energies president, talked about Project Kilby: a 20-year take-or-pay power purchase agreement with Microsoft for 2.67 gigawatts of behind-the-meter capacity to support a data center complex.JORDAN: This is Chevron essentially becoming a power supplier to AI infrastructure. And it's not small — they called it the only multi-gigawatt-scale project of its kind that's actually secured long-term customer commitments. Expected mid-teens returns, and cash flows that are independent of commodity price cycles, which is a really attractive diversification angle.ALEX: Wirth was pretty clearThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown of the companies moving the market. Today we're digging into Colgate-Palmolive's second quarter 2026 results. Before we get into it — quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And there was a lot to dig into here, Alex. This was a "good news, but with an asterisk" kind of quarter.ALEX: Exactly. Let's start with the headline numbers. Colgate delivered organic sales growth in four of five geographic divisions and three of four product categories. Gross margin expanded 100 basis points to a level that's up 90 basis points versus last quarter. Free cash flow was up 18%, and they returned $1.4 billion to shareholders. CFO Stan Sutula even raised the full-year gross margin guidance to roughly flat for the year — up from a prior expectation of a decline.JORDAN: That raise is notable because it's not just a fluke — management said it's coming from real execution: revenue growth management, productivity, favorable mix, plus a modest one-time tariff refund benefit that they don't expect to repeat.ALEX: Right, and CEO Noel Wallace was pretty upfront that this was a global story — emerging markets were the star again, up mid-single digits, led by India, Brazil, Mexico, and China.JORDAN: India in particular jumped out to me — double-digit growth in the quarter. And Latin America was strong too: Brazil up high single digits, Mexico mid-single digits, with a nice balance between pricing and volume. They're also lapping last year's Colgate Total reformulation issue, and those shares are coming back nicely, especially in Brazil.ALEX: But — and here's the asterisk — the U.S. business was the soft spot. Wallace didn't sugarcoat it, saying the North America team was "disappointed" with the quarter.JORDAN: Yeah, a few things stacked up there. May saw a sharp category slowdown tied to spiking gas prices hitting consumer confidence. There was heightened competitive activity, and retailers pulled back inventory — so shipments came in below actual consumption, roughly consumption flat versus shipments down 3%.ALEX: There was a great exchange with an analyst about that exact gap between what tracking data shows and what Colgate actually reports. Wallace admitted part of it is inventory destocking, but he was candid that they also lost a bit of share in untracked channels — so it's not purely a data mismatch, there's real competitive pressure in there too.JORDAN: What I liked was the specificity of the fix. It's not just "we'll try harder" — they identified select price gaps versus competitors in certain retailers and categories, and they're stepping up advertising in the back half, which is a real financial commitment given ad spend is already sitting near 20-year highs as a percentage of sales.ALEX: One analyst actually pushed on that — is 14% of sales the right ad spend level, or is that masking soft ROI given organic growth is only running 2 to 3%? Wallace's answer was basically: their data and digital measurement capabilities have improved a lot, ROI on digital and social specifically looks strong, and ultimately it's about long-term brand health, not just quarterly efficiency.JORDAN: Let's talk pets, because Hill's continues to be a genuine bright spot. Ex-private label, organic growth of 4%, well ahead of a category that's basically flat. The therapeutic and premium science-led segments are doing the heavy lifting there.ALEX: And there's a longer-term storyline brewing with the Prime brand and this new "Fresh" launch — single-protein, vet-recommended, science-first positionThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into AbbVie's second quarter 2026 results, and this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And Alex, this was another really strong quarter for AbbVie. Let's just get right into the numbers.ALEX: Yeah, so adjusted EPS came in at $3.65, which beat guidance by six cents. Total revenue was nearly $17 billion, up 10.2% year over year, and that beat expectations by $300 million. On the back of that, they raised full-year revenue guidance to about $67.6 billion — that's the second raise this year, $600 million total.JORDAN: What jumps out to me is the breadth of the growth. It's not just one drug carrying the load. SKYRIZI, RINVOQ, and the entire neuroscience portfolio all grew north of 20%. SKYRIZI alone did $5.5 billion in the quarter, up 24%. RINVOQ crossed $2.5 billion, up almost 24%.ALEX: And that's the story that matters most for AbbVie long-term — how well they've replaced the HUMIRA revenue. Speaking of which, HUMIRA sales were down 36% due to biosimilar competition, but that's expected and honestly just noise at this point given how much SKYRIZI and RINVOQ have scaled up.JORDAN: Right, HUMIRA is basically a rounding error now compared to where the immunology franchise is headed. Immunology overall did $8.8 billion, up nearly 15%.ALEX: Let's talk strategy, because the big headline this quarter was the announced acquisition of Apogee Therapeutics. This adds assets in dermatology, respiratory, and other inflammatory diseases — basically deepening that immunology pipeline for the 2030s and beyond.JORDAN: It's a dilutive deal in the near term — CFO Scott Reents said it's adding about 14 cents of dilution to full-year EPS guidance, which actually more than offset the underlying business over-performance in the updated guidance. But management framed it as setting up growth well past SKYRIZI and RINVOQ's patent cliffs.ALEX: Which, by the way, got some clarity on this call too. SKYRIZI's composition patent expires in 2033, but CEO Rob Michael pointed out regulatory data protection runs through 2031, and they don't expect biosimilar filings until the end of the decade. So that runway is longer than some investors might assume.JORDAN: The other big strategic thread was dermatology — RINVOQ picked up European approvals in vitiligo and alopecia areata, and management now sees combined peak sales for those two indications approaching $2 billion, which is well above what they'd previously guided.ALEX: There was a great exchange in the Q&A about that too — an analyst pushed on how crowded the vitiligo landscape is getting with other mechanisms coming in. Jeff Stewart's response was basically: these immunology markets keep proving to be way more expansive than people expect once a real systemic treatment shows up, and RINVOQ has the head start plus a decade of safety data behind it.JORDAN: I also want to flag the SKYRIZI subcutaneous induction story in Crohn's disease — that's got an FDA decision expected this fall. Jeff said they expect a "meaningful acceleration" in SKYRIZI's growth once that's approved, partly because it lets physicians avoid juggling two different reimbursement channels. Management expects that benefit to really show up in early 2027.ALEX: On the pipeline side, there's a lot cooking beyond immunology too. Parkinson's is shaping up as a real growth story — tavapadone has an FDA decision expected in Q3, and Vyalev is on track for blockbuster status this year. Management still sees the Parkinson's franchise collectively hitting more than $5 billion in peak sales.JORDAN: Oncology got some attThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Stryker's Q2 2026 results — and this is a good one, because it's really a comeback story.But first — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Okay, so context matters a lot here. Stryker got hit by a cybersecurity incident that knocked out manufacturing for about a month in Q1. So Q2 is really the "how fast can they recover" quarter.ALEX: And the answer is — pretty fast. Organic sales growth of 9%, adjusted EPS of $3.69, up almost 18% year over year. For a $25 billion company that had plants offline for weeks, that's a strong number.JORDAN: Right, CEO Kevin Lobo actually said it himself on the call — growing around 9% "given that we were knocked out for almost an entire month" is a pretty good outcome. And you saw strength pretty much everywhere: MedSurg and Neurotechnology up over 9%, Orthopedics up 8.6%. U.S. trauma and extremities grew over 12%, medical devices — Sage, Emergency Care — grew north of 13%.ALEX: The one soft spot was peripheral vascular, down almost 7% in the U.S. There was a supply disruption at one of their Inari manufacturing plants that caused a real backorder problem. They actually had to ration product to their best customers.JORDAN: Which is a rough thing to say out loud on an earnings call, but at least it's honest. Management expects that backorder to work itself down to manageable levels by the end of Q3, and they're still bullish long-term on that business — especially with the AVS acquisition that just closed, which adds an IVL, intravascular lithotripsy, product to the portfolio.ALEX: Let's talk strategy for a second, because there were some real headline moments here. Mako, their robotics platform, just turned 20 years old, and they had their best-ever second quarter for Mako installations, both in the U.S. and internationally. Over 2.5 million procedures done globally now, systems in 47 countries.JORDAN: And the bigger story is the full commercial launch of Mako RPS — that's their handheld robotics system. It's aimed at surgeons who aren't ready to commit to a full Mako cart, especially in ambulatory surgery centers doing total knees. Lobo said the haptic feedback is what's really wowing surgeons — that you can get that kind of precision in a handheld device.ALEX: They're also rolling out Triathlon Gold, a new insert for their knee system, a new total ankle replacement called Encompass, and a trauma plating system called Pangaea that's launching in Europe. So despite the manufacturing hit, the product pipeline didn't really slow down.JORDAN: Now, the money question everyone on the call kept circling back to — capital equipment. Stryker's sitting on an elevated order backlog because demand outpaced their ability to produce during the recovery. Beds, in particular — their ProCuity hospital bed business — has huge order volume they just haven't been able to fill yet.ALEX: And management's plan is straightforward: add manufacturing shifts and grind through the backlog in the second half of the year. Lobo was pretty confident about this, saying these aren't new products, this is stuff they know how to make — it's purely an execution and capacity question, not a demand question.JORDAN: That came up a lot in the Q&A, actually — analysts pushing hard on whether Stryker can really hit an implied 11% organic growth rate in the back half to reach their guidance midpoint. Lobo's response was basically, "we raised the low end of our guidance from 8% to 8.3%, that alone should tell you how confident we are."ALEX: On guidance — they narrowed the full-year range. OThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, bringing you straight talk on the numbers that move markets. I'm Alex.JORDAN: And I'm Jordan. Today we're digging into Intercontinental Exchange — ticker ICE — and their Q2 2026 results, reported Thursday, July 30th. And Alex, there's a lot here, including a headline-grabbing acquisition.ALEX: There really is. But first, the standard note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good, let's get into it. So ICE posted its best second quarter in company history. Adjusted EPS came in at $1.90 — a Q2 record. Net revenues hit $2.7 billion, up 5%, and recurring revenue was a record $1.4 billion, up 8%.ALEX: And what's notable is this is compounding on top of already-record growth in Q2 2025. CFO Warren Gardiner made a point of saying this quarter's story wasn't a volatility spike like Q1 — it was durability. Recurring, sticky revenue holding up even as episodic trading activity cooled off a bit.JORDAN: Right, and capital returns were strong too — $945 million back to shareholders this quarter, $1.8 billion in the first half, both records. Leverage sits at 2.8x, right in their target range.ALEX: But Jordan, let's talk about the big news — the $5.7 billion acquisition of MarketAxess.JORDAN: Yeah, this is the headline. ICE is paying $167 per share — a 33% premium — to buy MarketAxess, one of the leading electronic trading platforms for institutional bond markets. The strategic logic here is pretty elegant: ICE already dominates the retail and wealth side of fixed income trading through ICE Bonds. MarketAxess brings over 2,100 institutional clients — asset managers, pension funds, insurers.ALEX: So you're connecting two liquidity pools that historically never talked to each other.JORDAN: Exactly, and CEO Jeff Sprecher framed it as building "a global fixed income network" — retail flow meets institutional flow, all on common rails, layered with ICE's pricing and data. They're expecting about $100 million in annual expense synergies by year three, and management says it'll be accretive to earnings in year one.ALEX: Though a couple analysts pushed back a bit in the Q&A — MarketAxess has had some market share erosion and pricing pressure. Sprecher's answer was basically: we've been circling this space for a decade, and now the pieces — the data business, the treasury clearinghouse, the wealth channel — are finally in place to make the combination work.JORDAN: It's a cash deal, funded through bonds, a term loan, and commercial paper. Leverage will temporarily peak around 3.4x, but they're targeting back to 3x within 18 to 24 months. And despite taking on this debt, they're actually increasing quarterly buybacks from $350 million to $400 million.ALEX: Confidence signal there. Let's talk segments, because the underlying business had a strong quarter on its own, deal aside. Exchanges segment — $1.5 billion net revenue, and the rates business grew 24% year-over-year.JORDAN: That one's a great story. The ECB raised rates in June for the first time since 2023, and when central banks start moving — and moving in different directions from each other — that's exactly when ICE's European rate contracts get used. Open interest in their rates franchise hit a record 53 million contracts, up over 50% year-over-year.ALEX: And here's a stat that stuck with me — the total value of positions across their Euribor, SONIA, and ESTR contracts hit $62.3 trillion in mid-June. That's triple where it was three years ago, and it now exceeds the comparable U.S. dollar rates market.JORDAN: That's wild. Meanwhile, Fixed Income and Data Services net revenue was $645 million, up 8%, with their CDS clearinThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Bristol Myers Squibb's second quarter 2026 results, reported Thursday morning. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And BMY shares were up nearly 2.8% on the news, so investors clearly liked what they heard. Let's get into the numbers.ALEX: Total revenue for Q2 came in around $13 billion, up 5% year-over-year. The headline story here is what they call the "growth portfolio" — that's their newer drugs — now making up almost 60% of total revenue, growing 14%. Ten different products posted double-digit growth.JORDAN: That's the story management really wants you to hear — they're successfully transitioning away from legacy products losing patent protection, toward newer assets. And the standouts were impressive: Reblozyl up 29%, Breyanzi up 41%, Camzyos up 59%, and Qvantig — the newer version of their big cancer drug Opdivo — now annualizing over $1 billion.ALEX: Meanwhile, on the "legacy" side, Eliquis, their blood thinner, actually grew 21% on strong demand, which helped offset declines elsewhere from generic competition, especially as Revlimid keeps facing generics.JORDAN: Diluted EPS was $2.04 for the quarter, and gross margin held at 71.4%. And because of this strength, management raised full-year guidance for both revenue and adjusted EPS.ALEX: They also raised their Eliquis growth expectation for the year to 20-25%, and said the overall legacy portfolio decline will be less severe than previously thought — now 4-6% instead of worse.JORDAN: Balance sheet's solid too — $11.5 billion in cash, $3.4 billion in operating cash flow for the quarter, and they paid down $1.2 billion in debt. So they've got room to keep investing.ALEX: Now let's talk strategy, because there's a lot happening on the pipeline side. CEO Chris Boerner talked about the company potentially launching more than 10 new medicines by the end of the decade, plus over 30 lifecycle management opportunities.JORDAN: The near-term catalyst everyone's watching is iberdomide — that's their CELMoD, a new class of oral drug for multiple myeloma. It has an FDA decision date of August 17th, so basically two weeks after this call. If approved, it'd be the first commercialized CELMoD ever.ALEX: And there's a second one right behind it — mezigdomide — which just got its FDA application accepted with a target decision date of May 2027. Management's pretty bullish these two drugs, along with a third one called golcadomide, could eventually replace older myeloma standards like Revlimid and Pomalyst.JORDAN: But here's the more nuanced part of the call — two of their biggest pipeline bets just got delayed. Milvexian, a next-generation blood thinner they're developing with Johnson & Johnson... wait, actually it's with partners on the anticoagulant side, competing against their own Eliquis franchise — its atrial fibrillation trial readout got pushed from late 2026 to Q1 2027.ALEX: And separately, Cobenfy — their schizophrenia drug that they're also testing in Alzheimer's-related psychosis — those readouts are now expected to start in early 2027 instead of this year.JORDAN: Now, management was pretty insistent both delays are actually good news in disguise. For milvexian, it's an event-driven trial — meaning they need a certain number of stroke and bleeding events to occur before they can read the data. Fewer events happening means the drug might be working better than expected. Chief Medical Officer Cristian Massacesi even pointed out that a competitor's similar trial got stopped early for going the wThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: FAANG (https://betafinch.com/groups/FAANG), MAG7 (https://betafinch.com/groups/MAG7), AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the earnings call transcripts you don't have time to read and turn them into a conversation you can actually enjoy. I'm Alex.JORDAN: And I'm Jordan. And Alex, before we dive into Amazon's Q2 numbers, which are honestly wild—ALEX: They are, but first — a quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good, glad that's out of the way, because we've got a lot to unpack.ALEX: Let's start with the headline numbers. Amazon posted $200.6 billion in revenue for Q2 2026, up 20% year-over-year. Operating income came in at $27.5 billion, up 43%. But the real story, as usual these days, is AWS.JORDAN: AWS grew 36.7% year-over-year — and that's the fifth straight quarter of acceleration. Fastest growth in 18 quarters, back when the business was less than half its current size. They added $4.6 billion in revenue quarter-over-quarter, about 80% more than their biggest jump ever.ALEX: And the run rate — AWS is now annualizing at $169 billion. Andy Jassy pointed out that would rank 24th on the Fortune 500 as a standalone company. That's not a division anymore, that's a Fortune 25 company.JORDAN: The backlog is the number that jumped out at me though — $496 billion, growing triple digits year-over-year. That's demand they haven't even fulfilled yet.ALEX: Right, and that ties into the CapEx story. Amazon bumped its 2026 cash CapEx guidance from about $200 billion to $220 billion, mostly because of higher memory chip costs. Jassy spent a good chunk of the call explaining the math behind that — data centers take about two years to build but then monetize for 30-plus years, while servers break even in under three years and run five to six years. It's basically Amazon saying "trust the ROIC math," even while free cash flow takes a hit in the near term.JORDAN: And CFO Brian Olsavsky backed that up on margins — AWS operating income was $16.6 billion, a 39% operating margin. That's up 650 basis points year-over-year, or 520 if you strip out a one-time derivative accounting gain on energy contracts. An analyst on the call, Doug Anmuth, basically asked "shouldn't AI workloads be dragging margins down?" and the answer was: not so far, thanks to efficiency gains and capacity optimization.ALEX: Speaking of AI specifically — two numbers stood out. Amazon's chips business, that's Trainium and Graviton, now has an annual revenue run rate over $25 billion, growing triple digits. And separately, AI revenue overall also crossed $25 billion run rate. Both Anthropic and OpenAI have made multi-year, multi-gigawatt commitments to Trainium.JORDAN: There was also a really interesting exchange about whether Amazon needs its own frontier model. Jassy's answer was basically "no, but we're building one anyway" — for cost control, prioritization, and speed, not because Bedrock needs it to survive. His view is there won't be one model to rule them all, there'll be half a dozen comparably good frontier models within a few years, and Amazon wants to be one of them while still hosting all the others in Bedrock.ALEX: There was also news that Amazon is exploring selling Trainium chips directly to third-party data centers, separate from AWS cloud. Jassy said there's "a real chance" that happens.JORDAN: Let's talk Stores for a second, because it's easy to get AWS tunnel vision on these calls. Worldwide paid units grew 17%, North America revenue hit $116.2 billion, up 16%. Grocery is a big theme — Amazon says it's now the second-largest grocer in theThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Regeneron's second quarter 2026 results, and Jordan, this was a big one.JORDAN: A really strong quarter across the board. But first, the standard note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.ALEX: Right. So let's set the scene — before diving into numbers, the call opened with a tribute to longtime board member Art Ryan, who passed away this week. He'd been on Regeneron's board for over two decades, previously ran Prudential. A nice moment of the human side of these calls.JORDAN: Definitely worth noting. Now, onto the business — total revenue was up 17% year-over-year to $4.3 billion, and non-GAAP EPS grew 11% to $14.29. That's their second straight quarter of double-digit growth on both lines.ALEX: And the headline here is really the trio of record quarters — Dupixent, EYLEA HD, and Libtayo all hit all-time highs for quarterly sales.JORDAN: Let's start with Dupixent since it's the big one. Global net sales hit $6 billion, up 38% on a constant currency basis. U.S. sales alone grew 42% to $4.6 billion. That's a drug now serving over 1.5 million patients across nine approved indications.ALEX: Nine! That's dermatology, asthma, nasal polyps, COPD, eosinophilic esophagitis — it just keeps expanding. And here's something investors should watch: Regeneron fully repaid its $3.1 billion development balance owed to Sanofi. That balance had been suppressing collaboration revenue — about $930 million lower in 2025 and $530 million in the first half of this year.JORDAN: So starting in Q3, Regeneron gets to keep its full share of collaboration profits. That's a real step-up to the bottom line going forward, not tied to any new sales growth — just an accounting unlock.ALEX: Exactly. Now let's talk EYLEA HD — this one's on fire. U.S. net sales just under $600 million, up 52% year-over-year. And notably, this was the first quarter EYLEA HD sales actually exceeded the original EYLEA.JORDAN: That's the conversion story playing out. EYLEA HD now makes up about 60% of the franchise, up from 34% a year ago. Meanwhile legacy EYLEA sales fell 45% as patients and doctors shift over — plus there's now biosimilar competition entering that older product's market.ALEX: They're also awaiting FDA approval on an EYLEA HD prefilled syringe, which could drive even more adoption. Management sounded confident that could land by year-end.JORDAN: And rounding out the trio, Libtayo — their oncology drug — hit $489 million globally, up 29%. It's gaining real traction in non-small cell lung cancer, now capturing 20% of new prescriptions, double what it was just last year.ALEX: Let's talk pipeline for a second, because Regeneron's whole philosophy here is "don't bet on one horse." They've got roughly 50 active clinical programs.JORDAN: A few near-term catalysts stood out to me. There's cemdisiran, their siRNA therapy for myasthenia gravis, with an FDA decision expected in November — that could be the first siRNA approved for that disease. There's also garetosmab for a rare bone disease called FOP, with an FDA decision expected as soon as August.ALEX: And on the bigger picture front, they're moving into Phase III trials later this year for both their obesity program — a GLP-GIP combo called olatorepatide — and their anticoagulation program targeting Factor XI, which is a different approach than the traditional blood thinners on the market.JORDAN: One thing that came up repeatedly in Q&A was the Sanofi relationship. CEO Leonard Schleifer confirmed they're in "productive early discussions" with Sanofi about expanding the collaboratioThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: FAANG (https://betafinch.com/groups/FAANG), MAG7 (https://betafinch.com/groups/MAG7)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Apple's fiscal Q3 2026 results, and Jordan, there is a LOT here — record numbers, a CEO transition, and a whole conversation about memory chip prices that got surprisingly dramatic.JORDAN: Before we get into any of it, quick note for everyone listening — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.ALEX: Right, so let's start with the headline number: $109.4 billion in revenue, up 16% year-over-year, a June quarter record. iPhone alone did $54.3 billion, up 22%. Mac had its best June quarter ever at $10.4 billion, up 29%. Services hit $30.7 billion, also a record.JORDAN: Those Mac numbers jumped out at me the most. 29% growth is huge for a product line that's usually pretty steady. That's the MacBook Neo and MacBook Pro doing real work — and they set records for both new customers and upgraders, including in the U.S., China, and India.ALEX: And this all happened despite supply constraints, which becomes a big theme later in the call. Profitability-wise, gross margin was 50.1%, EPS was $2.02, up 29%. But here's the asterisk — a chunk of that came from tariff refunds, worth about two percentage points on gross margin and 11 cents on EPS.JORDAN: Right, so strip that out and it's still a solid quarter, just not quite as flashy as the headline. Operating cash flow was $34.4 billion, also a record even without the tariff benefit. So the underlying business is genuinely strong.ALEX: Now let's talk about the elephant in the room — memory prices. Tim Cook called this a "100-year flood" on memory pricing.JORDAN: That phrase is going to get quoted a lot. Basically, DRAM costs have been spiking quarter after quarter — more expensive in March than December, more in June than March, and they're expecting even higher costs in September. Apple's offsetting some of it with leftover inventory and cheaper non-memory components, but that cushion is fading.ALEX: And this is part of why Apple actually raised prices on iPad and Mac — which Cook admitted was reluctant. He was pretty candid that they look at units, revenue, and margin together rather than defending one metric in isolation.JORDAN: The other supply story is the September guide. Apple's guiding 9-11% revenue growth for the quarter, which is a real deceleration from the mid-teens they'd been running. Analysts pushed hard on this, and Cook was clear it's not a partner or vendor issue — it's that iPhone and Mac demand outran their forecasts, and there's just less flexibility in the advanced-node chip supply chain than usual.ALEX: Which is kind of a good problem to have, but still a real one for the next couple quarters. FX is also a headwind — about two and a half points sequentially — so between currency and supply, that explains most of the slowdown.JORDAN: Services is worth flagging too. 12% growth was a touch below expectations, mostly FX plus some softness in mobile gaming on the App Store. But cloud services and payment services hit all-time records, and Apple now has over one and a half billion paid subscriptions. So the growth engine's still running, just facing more currency drag than the hardware side.ALEX: Now, the big non-financial story — this was Tim Cook's final earnings call. He's handing the CEO role to John Ternus, who was on the call and fielded a question about competitive threats.JORDAN: Ternus kept it pretty measured — didn't take the bait on OpenAI or SpaceX device rumors, just said Apple's focused on its own roadmap. Cook, on the other hand, got a little sentimental, thanking shareholders and analystsThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: ENERGY (https://betafinch.com/groups/ENERGY)──────────WELCOME TO BETA FINCH — SOUTHERN COMPANY (SO) Q2 2026ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Southern Company's second quarter 2026 results. Before we get into it — quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And Alex, this is a fun one — because Southern Company isn't just beating numbers this quarter, they're sitting at the center of the whole AI infrastructure buildout story. Data centers, hyperscalers, nuclear — it's all here.ALEX: Let's start with the headline numbers. Adjusted EPS for Q2 came in at $1.13 per share — that's $0.21 higher than Q2 last year, and $0.13 above what they'd guided last quarter. First half of the year, adjusted EPS is $2.46, well ahead of expectations.JORDAN: And because of that strength, management now expects full-year 2026 adjusted EPS to land near or at the top of their guidance range of $4.50 to $4.60. They also gave Q3 guidance of $1.65 a share. So they're not just beating — they're raising the bar for the rest of the year.ALEX: What's actually driving this? CFO David Poroch pointed to increased usage and customer growth, higher AFUDC — that's allowance for funds used during construction, basically a return utilities earn while big projects are being built — plus earnings from equity investments and some favorable tax impacts.JORDAN: The sales growth numbers are honestly the headline for me. Weather-normal retail electricity sales were up 2.3% year-to-date — the strongest growth through June in almost two decades. And get this: data center usage was up 55% compared to Q2 last year, and system-wide data center load now exceeds 1.2 gigawatts.ALEX: That's the story everyone's watching right now — power demand from AI data centers. And Southern just landed a massive one. Georgia Power signed a 3.2 gigawatt, 25-year contract with OpenAI for a site near Savannah.JORDAN: Twenty-five years, Alex. That's the kind of contract length that makes utility investors sit up. And it's not a standalone number — combined with three new projects in Alabama totaling about 3 gigawatts, Southern's total contracted large-load demand is now over 17 gigawatts through the mid-2030s.ALEX: And the pipeline behind that is enormous — CEO Chris Womack said their prospective pipeline of large industrial and data center projects remains "well above 75 gigawatts," with another 8 gigawatts in late-stage development, 3 of which could finalize soon.JORDAN: What I liked in the Q&A was how much attention they paid to protecting existing customers from this growth. Chris Womack talked about the National Ratepayer Protection Pledge they just joined, and the contract structure — minimum bills that cover 100% of the incremental cost to serve, plus serious collateral backing.ALEX: That collateral detail was wild. On a question from Wolfe Research's Steve Fleishman, David Poroch clarified that across the full 17-gigawatt portfolio of large-load contracts, Southern's holding about $21 billion in collateral — lines of credit, surety bonds, parent guarantees — enough to keep their effective credit exposure around an A-minus or better, even when the counterparty itself isn't quite investment grade.JORDAN: That's a smart risk-management story for a company taking on this much new, concentrated demand. And it's part of why they can say retail base rates are staying stable in Georgia and Alabama through 2029 — even as they're plugging in gigawatts of new load.ALEX: The OpenAI deal also included something new — one gigawatt of flexible demand response, meaning OpenAI's site can dial back uThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: INCOME (https://betafinch.com/groups/INCOME)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Altria Group's second quarter 2026 results. I'm Alex, joined as always by Jordan. And before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Good to be here, Alex. And there's actually a lot to unpack this quarter — Altria raised guidance, but the story underneath it is more nuanced than the headline suggests.ALEX: Let's start with the numbers. Adjusted diluted EPS came in at $1.48 for the quarter, up 2.8%. For the first half of the year, that's $2.80, up a healthier 4.9%. And on the back of that first-half strength, Altria narrowed — and actually raised the low end of — full-year guidance to a range of $5.61 to $5.72, which works out to 3.5% to 5.5% growth off last year's base.JORDAN: Right, but here's the interesting wrinkle — one analyst on the call pointed out that even with that raised low end, it's still below what they delivered in the first half. So the second-half math implies things moderate a bit. CEO Sal Mancuso's answer basically boiled down to: the consumer is still under pressure — elevated gas prices, inflation — and they're stepping up investment behind new launches, so don't expect the same pace of growth to just continue in a straight line.ALEX: That's a good instinct as a listener — when a company raises guidance but the low end still trails first-half performance, it's worth asking why. In this case it sounds like a mix of planned investment spend and just conservative phasing.JORDAN: Exactly. Now let's talk about where the real growth engine is: smokeable products. That segment's adjusted operating income grew 4.2% in the first half, with margins expanding to nearly 65%. Cigarette volume declines are actually moderating — down about 5% industry-wide when you adjust for inventory, and that's the fourth straight quarter of that decline rate improving.ALEX: Why is that happening? Management pointed to something pretty specific — fewer smokers switching over to illicit flavored disposable vapes, largely because of stepped-up enforcement. Federal seizures topped $250 million this quarter alone, plus a Minnesota AG lawsuit against a major illicit vape manufacturer.JORDAN: Which is a fascinating dynamic — Altria's traditional cigarette business is getting a tailwind from regulators cracking down on unregulated vape products. That's basically the whole thesis of tobacco harm reduction policy playing out in real time, just not in the direction some might expect.ALEX: Meanwhile, within cigarettes, there's a real trade-down story happening. Discount segment share grew 2.6 points as lower-income consumers feel the pinch. Marlboro held its premium leadership — 59.6% share of premium — but its overall share dipped 1.5 points as some smokers shift to value options.JORDAN: And Altria's playing both sides of that. They launched Marlboro Cowboy Cut — a value-oriented Marlboro line tied to America's 250th anniversary, clever branding there — while also growing their Basic discount brand, which saw share up 2.3 points year-over-year. Management was clear: the strategy is to participate in discount without accelerating the category's growth, protecting Marlboro's premium position as much as possible.ALEX: Let's shift to the smoke-free side, because this is where the long-term story lives. The oral tobacco segment actually had a rough quarter on paper — adjusted OCI down 8% — but that's largely due to tough prior-year comparisons and heavy investment behind on! PLUS, their new nicotine pouch line.JORDAN: Right, and context matters here. Nicotine pouches are now nearly 60% of the entiThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Starbucks' fiscal Q3 2026 results, and Jordan, this one's got some real momentum behind it.JORDAN: It really does, Alex. But before we get into all the green apron talk and coffee comps, quick disclaimer for everyone tuning in: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.ALEX: Well said. Okay, let's get into it. Starbucks posted its fourth consecutive quarter of positive global comps — global comps up 7.9%, which actually accelerated sequentially from Q2. U.S. comps came in at 7.9% too, with a healthy split between transactions up 4.2% and ticket up 3.6%.JORDAN: And that composition really matters. It's not just price hikes doing the work — pricing only added less than a point to ticket growth. This is genuine traffic and spend growth, which is a much healthier story than an earnings beat propped up by inflation.ALEX: Right, and the profitability story is where things get really interesting. Consolidated operating margin expanded 430 basis points year-over-year to 14.4%. EPS jumped 70% year-over-year to $0.85.JORDAN: Now, a chunk of that margin story includes some noise — tariff refunds that offset tariffs incurred earlier in the fiscal year. CFO Cathy Smith was upfront about that, pointing analysts to the year-to-date COGS rate of 32.3% as the more "normalized" number. But even stripping out those refunds, North America margin still expanded over 100 basis points year-over-year. That's the real signal — the underlying operating model is actually getting better, not just benefiting from a one-time tailwind.ALEX: Big milestone too — North America operating margin grew year-over-year for the first time since Q1 fiscal 2024.JORDAN: That's a notable inflection point. It tells you the "Back to Starbucks" plan under CEO Brian Niccol is finally translating into bottom-line results, not just top-line traffic.ALEX: Speaking of the plan, let's talk Green Apron Service — this is basically the operational backbone of the turnaround. It's been a year since launch, and two-thirds of North America company-operated stores are now hitting four or more "shots" on their internal ranking system, up over 40 points since launch.JORDAN: And food availability is now near 99%, up about 10 points from a year ago. Store leader retention is up too — leaders who've been in place two-plus years rose about 7 points year-over-year. That stability piece is easy to overlook, but management specifically called out that it correlates strongly with store performance.ALEX: They also rolled out a new incentive — the Best of Starbucks Reward — letting eligible partners earn up to $300 a quarter for hitting performance goals. A nice retention lever.JORDAN: On the brand side, some striking numbers: brand affinity, consideration, and purchase intent all hit five-year highs. Starbucks Rewards now has 35.8 million 90-day active U.S. members, and Refreshers delivered double-digit revenue growth in the U.S. Management's clearly leaning into that platform — they're even testing a sparkling "Spritzer" version.ALEX: The store uplift program is another one to watch — they crossed 1,000 remodeled stores in North America, hit their full-year goal early, and now they're targeting at least 1,500 by the end of fiscal 2026, accelerating further into 2027. Cathy Smith mentioned these average around $150,000 each and get done overnight without taking stores offline.JORDAN: Efficient capital use, basically — cheap relative to a full remodel, and the early data shows transaction lift across all dayparts and formats. Meanwhile, internationally, the China businThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: CHIPS (https://betafinch.com/groups/CHIPS)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Qualcomm's fiscal Q3 2026 results — a quarter that's part strong execution, part serious cost headwinds. Before we get into it, quick note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Alright, let's get into the numbers. Qualcomm posted revenue of $9.9 billion, high end of guidance, and non-GAAP EPS of $2.21. QCT — that's their chip business — brought in $8.5 billion, and licensing added $1.3 billion. On the surface, solid. But there's a real story underneath these numbers.ALEX: Right, and that story is memory prices. CEO Cristiano Amon was upfront that the whole industry is dealing with a spike in memory costs, plus higher manufacturing and packaging costs, and supply shortages tied to data center demand sucking up capacity. That's squeezing QCT gross margins below their historical range this quarter.JORDAN: Their answer is price increases — double-digit, broad-based across end markets, according to CFO Akash Palkhiwala. But here's the nuance: it phases in gradually because of existing contracts and product cycles. Amon actually made an interesting point on the call — even a double-digit chip price increase is small compared to the magnitude of memory cost inflation hitting device bills of materials.ALEX: So this isn't really Qualcomm gouging anyone, it's a pass-through of what's happening across the whole supply chain. And notably, they said they expect fiscal 2027 top-line growth despite all this, driven by an inflection in their non-handset businesses.JORDAN: And that's really the headline of this call — the diversification story. At their recent Investor Day, they raised their fiscal 2029 non-handset revenue target from $22 billion to $40 billion. That includes over $24 billion from automotive and IoT, plus more than $15 billion from data center.ALEX: Let's talk data center, because this is the new frontier for Qualcomm. They're rolling out four product lines over the next few years — connectivity starting this year, custom silicon and AI accelerators in fiscal 2027, and server-class CPUs by fiscal 2028. They've already got two custom silicon deals with what they describe as global-scale hyperscalers, and revenue from those starts in the December quarter.JORDAN: They also completed the tape-out of their High Bandwidth Compute chip — HBC Gen 1 — which integrates compute directly with high-density memory. First commercial HBC product is targeted for mid-2027. And they closed the acquisition of Modular, an AI software company, to build out an end-to-end, hardware-agnostic software stack. Worth noting though — Stacy Rasgon from Bernstein asked about margin drag from data center, and Akash confirmed it: expect a 1.5 to 2 percentage point drag on QCT's weighted average gross margin as that early revenue comes online, since it's mostly lower-margin custom chip work initially.ALEX: Automotive was the clear bright spot this quarter — record revenue of $1.6 billion, up 61% year-over-year. They also signed a landmark expanded deal with BMW to be the lead compute silicon provider for next-gen ADAS and digital cockpit, plus a Stellantis collaboration stretching into the 2030s.JORDAN: And they raised their automotive run-rate target — previously $6 billion annualized exiting fiscal 2026, now bumped up to about $7 billion. That's a meaningful upward revision in just one quarter.ALEX: Now let's talk about the elephant in the room — Apple. This was probably the most eyebrow-raising part of the call.JORDAN: Yeah, Akash disclosed that Qualcomm's share of the upcoming iPhone launch will be materially lower thanThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: MAG7 (https://betafinch.com/groups/MAG7), AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)──────────MSFT Q4 FY26 script.ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.JORDAN: And I'm Jordan. Today we're digging into Microsoft's fiscal fourth quarter and full-year FY2026 numbers.ALEX: Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Solid disclaimer out of the way, let's talk numbers, because this was a genuinely strong quarter for Microsoft.ALEX: Big picture first: full fiscal year revenue crossed $331 billion, up 18%, and that growth actually accelerated through the year. Microsoft Cloud alone did over $214 billion, up 27%, and Azure crossed the $100 billion mark, up 41% for the year.JORDAN: And for the quarter itself, revenue was $90 billion, up 18%. EPS came in at $4.74, up 23% when you adjust for the OpenAI investment impact. There were some one-time items too — a $3.2 billion gain from their Anthropic investment, some savings from a voluntary retirement program, offset partly by Xbox severance and impairment charges.ALEX: Azure was really the headline. Growth hit 43% this quarter, and CFO Amy Hood said they expect it to accelerate into the mid-40s next quarter. That's remarkable for a business already this large.JORDAN: Right, and what stood out to me is *why* it accelerated — it wasn't just demand, which is still outstripping supply, by the way. It was efficiency. They shaved dock-to-live time for new GPUs by nearly 50% over the year, and any capacity they free up gets monetized almost immediately because demand is so far ahead of supply.ALEX: That supply-demand gap is clearly the story of this whole AI infrastructure buildout. They added 31 new data centers this quarter alone, 88 for the year, and they're on track to roughly double total capacity in just two years.JORDAN: Which explains the capex number — $41 billion this quarter, and guidance for next fiscal year points to over $175 billion, partly due to an accounting change where more data center leases shift from finance leases to operating leases. That's not new spending, just a reclassification, but it's worth knowing so you don't misread the capex jump.ALEX: Let's talk Copilot, because the seat growth was eye-catching — over 30 million paid Microsoft 365 Copilot seats, and net seat adds more than doubled quarter over quarter.JORDAN: What I found more interesting than the seat count was the usage data. Conversations per user nearly doubled year-over-year, and time from deployment to high usage across a customer's workforce dropped from months to just days. Satya Nadella also mentioned the number of customers with 50,000-plus seats grew over 7x year-over-year. NHS England alone is rolling Copilot out to over 500,000 clinicians and staff.ALEX: And they're clearly trying to move the business model beyond simple per-seat pricing. The new E7 suite bundles Copilot, E5, Entra, and Agent 365 together, and they're layering in usage-based billing on top of seats — same playbook they used with GitHub Copilot, where consumption revenue jumped after a June pricing change and Copilot revenue accelerated over 60% quarter-over-quarter.JORDAN: That model-choice strategy came up a lot in the Q&A too. An analyst asked Satya directly about open and custom models potentially cutting into Microsoft's own frontier-model partnerships, like OpenAI.ALEX: And his answer was essentially: enterprises want to control their own "learning machine" — keep the harness, memory, and context separate from any single model so they're never locked in. Microsoft's building itself as the neutral platform where that choice happens, whether it's OpenAI, AnthrThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: FAANG (https://betafinch.com/groups/FAANG), MAG7 (https://betafinch.com/groups/MAG7), AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Meta Platforms' Q2 2026 results. Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And there's a lot to unpack this quarter. Meta posted $60.8 billion in total revenue, up 28% year-over-year. Ad revenue alone hit $59.4 billion, up 27%.ALEX: Zuckerberg opened by pointing out 3.6 billion people use at least one Meta app daily. Instagram hit 2 billion daily actives, Threads crossed 500 million monthly actives, and WhatsApp set an all-time messaging record during the World Cup final — 30 million messages a second.JORDAN: That scale is the whole thesis here, honestly. Everything Meta wants to do with AI — better recommendations, better ads, agents — it all rides on that massive built-in audience. But let's talk numbers first, because there's some nuance. GAAP operating income was actually down 8% year-over-year, to $18.8 billion.ALEX: Right, but that's a bit misleading on its face. That includes a $2.4 billion legal charge and $1.2 billion in severance from the May headcount reduction — about 8,000 employees.JORDAN: Exactly, strip those out and operating income would've been up 9% year-over-year. Net income landed at $15.8 billion, or $6.18 per share. Free cash flow, though, only $784 million — that's a steep drop, mostly because CapEx is running hot.ALEX: Which brings us to the big number everyone's watching: capital expenditures. $31.1 billion this quarter, and full-year 2026 guidance got narrowed upward to $130-145 billion.JORDAN: That's an enormous number. And they just announced a new venture with BlackRock for a one-gigawatt data center in El Paso, Texas — a sign they're leaning on outside capital, not just their own balance sheet, to fund this build-out.ALEX: Susan Li made a point of that on the call — evolving their capital structure to include more debt, plus these external partnerships, to keep funding infrastructure without straining the core business.JORDAN: Now let's get into the strategy, because Zuckerberg laid out basically three pillars. One, AI accelerating the core business — ads and recommendations. Two, personal agents as the next big consumer product. Three, an enterprise play — selling APIs, business agents, and even compute directly to other companies.ALEX: The core business numbers back that up already. They introduced something called Meta Generative Recommender — using LLMs to match ads and users together rather than scoring ads one by one. That drove an 8.3% increase in ad clicks and a 15.7% uplift in conversions on Facebook.JORDAN: Those are real, tangible performance gains, not just hype. And on the content side, Instagram time spent grew double digits year-over-year, largely from better Reels and feed recommendations powered by these LLM systems.ALEX: Then there's the more speculative stuff — personal agents. Zuckerberg was pretty candid that they haven't shipped this yet. He talked about it a lot but kept saying "we'll have more to share soon."JORDAN: Which is interesting contrast to business agents, where they actually have traction now — over 1 million businesses using Meta Business Agents weekly across WhatsApp and Messenger. There was a great example: Movida, a Brazilian rental car company, saw a 44% increase in daily bookings through WhatsApp, with 85% of conversations resolved entirely by AI without human help.ALEX: That's a concrete enterprise proof point. On the Q&A front, one exchange stood out to me — Morgan Stanley's Brian Nowak asked which ofThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: CHIPS (https://betafinch.com/groups/CHIPS)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, bringing you the numbers and the narrative from Wall Street's biggest movers. I'm Alex, joined as always by Jordan. Today we're digging into Lam Research's June quarter, fiscal Q4 2026 — and Jordan, this one's a barnburner.Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: With that out of the way — Alex, Lam just closed out fiscal 2026 with records stacked on records. Fourth straight quarter of record revenue, highest gross margin in 20 years, record operating margin, record EPS. This is a semiconductor equipment maker riding the AI capex wave about as well as anyone.ALEX: Let's hit the headline numbers. June quarter revenue came in at $6.72 billion, up 15% sequentially and 30% year-over-year. Gross margin hit 52%, operating margin 38.4%, diluted EPS a record $1.82 — all above the high end of guidance. For the full fiscal year, revenue was $23.2 billion with EPS of $5.82, up 41% from fiscal 2025.JORDAN: And the guide for September is even bigger — $8.1 billion, plus or minus $400 million. That's more than 20% sequential growth. CEO Tim Archer also raised his calendar 2026 wafer fab equipment spending outlook to the "low $150 billion range," up from the prior $140 billion call.ALEX: What jumped out to me was NAND. Revenue there literally doubled sequentially. Archer tied that directly to AI — bigger context windows, persistent memory requirements, all of it pushing customers to upgrade their fabs to 200-plus layer NAND architectures.JORDAN: Right, and this is where the story gets interesting for the long haul. Archer said Lam's served available market — SAM — per wafer in NAND could double again as layer counts climb from 128-layer to 500-plus layer devices. More layers means more etch and deposition steps, and etch and deposition is Lam's bread and butter.ALEX: They also talked a lot about advanced packaging — TSV etch and electroplating for things like HBM. That segment's growth outlook has basically been revised upward every quarter this year — from 40%, to 50%, now to over 70% year-over-year growth.JORDAN: And it's not just chasing today's demand. Archer mentioned future AI packages could be nine times the size of a standard reticle — three times larger than today's chips — which is pushing the whole industry toward panel-level packaging instead of traditional wafers. Lam's already shipped panel-format tools into development programs, so they're trying to get ahead of that transition.ALEX: Let's talk margins for a second, because CFO Doug Bettinger got some pointed questions on this. Analysts pushed him on how Lam gets from today's 51-52% gross margin to the "mid-50s" long-term target they've now laid out — up from the "high-40s to 50%" framework from their 2025 investor day.JORDAN: His answer was basically: it's a mix of scale, operational efficiency — a lot of credit went to their global manufacturing footprint, including that Malaysia facility JPMorgan's analyst asked about — plus new product introductions and, yes, pricing. But he was clear it's going to take "several years," not quarters.ALEX: One exchange I loved was the debate over 2027. Multiple analysts tried to get Bettinger to put a number on next year's growth, and he wouldn't bite, but he kept saying things like "pretty darn good year" and that he feels "incrementally good" about each successive quarter. The industry is still undersupplied — there are reportedly eight to ten new fabs coming online globally between now and the end of 2027.JORDAN: That undersupply point matters. Bettinger also updated a framework they'd fThis episode includes AI-generated content.